SQV nucleic acids and polypeptides

Abstract

The invention generally features sqv nucleic acid and polypeptide molecules associated with connective tissue diseases, progeroid disorders, and aging, and methods for isolating such molecules.

Description

BACKGROUND OF THE INVENTION

[0003] The invention is in the field of nucleic acid and polypeptide molecules associated with connective tissue diseases, progeroid disorders, and aging; methods for isolating such molecules; and the use of such molecules in human and veterinary practice.

[0004] Recently, recognition of the importance of glycosaminoglycans in animal development and human health has grown. Mutations in a human glycosaminoglycan (GAG) biosynthetic enzyme, galactosyltransferase I, may cause a progeroid variant of the connective-tissue disorder Ehlers-Danlos syndrome (EDS), a group of heritable disorders characterized by hyperelasticity of the skin and hypermobile joints.

[0005] Another GAG biosynthetic enzyme, murine EXT1, is a glycosyltransferase required for polymerization of the repeating disaccharides of heparan sulfate. Mutations in the human EXT tumor suppressor gene family are associated with a hereditary disorder, hereditary multiple exostoses (HME) that is characterized by multiple cartilaginous tumors that can be transformed to chondrosarcomas or osteosarcomas. The identification of additional mammalian genes that encode proteins that function in GAG synthesis will benefit our understanding of the role that GAG's play in human health and disease. In addition, therapeutic agents are required to modulate GAG biosynthetic pathways for the treatment of connective tissue diseases and disorders.

SUMMARY OF THE INVENTION

[0006] We have identified and characterized a number of nucleic acid molecules and polypeptides that function in eukaryotic glycosaminoglycan (GAG) biosynthetic pathways. Given the functional and structural similarities to human proteins, C. elegans wild-type and mutant worms will be useful in screening for compounds that modulate eukaryotic GAG biosynthetic pathways. The invention provides a number of targets that are useful for the development of drugs that specifically enhance or inhibit a eukaryotic GAG biosynthetic pathway. In addition, the methods of the invention provide a facile means to identify compounds that are safe for use in eukaryotic organisms (i.e., compounds which do not adversely affect the normal development and physiology of the organism), and efficacious in modulating a GAG biosynthetic pathway (i.e., by enhancing or inhibiting the activity of a SQV polypeptide). In addition, the methods of the invention provide a route for analyzing virtually any number of compounds for an effect on a eukaryotic GAG pathway with high-volume throughput, high sensitivity, and low complexity. The methods are also relatively inexpensive to perform and enable the analysis of small quantities of active substances found in either purified or crude extract form. Drugs that target a eukaryotic glycosaminoglycan biosynthetic pathway are useful in the treatment or prevention of connective tissue diseases and disorders. Moreover, insights into the C. elegans GAG biosynthetic pathway will benefit our understanding of the role of GAGs in human health and disease.

[0007] In a first aspect, the invention generally features a method of identifying a compound that modulates a glycosaminoglycan biosynthetic biological activity, the method involves (a) providing a cell containinga sqv nucleic acid molecule; (b) contacting the cell with a candidate compound; and (c) detecting an alteration in a glycosaminoglycan biosynthetic biological activity of the cell, where the alteration identifies the compound as modulating a glycosaminoglycan biosynthetic biological activity. In some embodiments, the cell is a mammalian cell or a nematode cell. In a preferred embodiment, the nematode cell is in a nematode and the alteration is of a vulval phenotype. In other embodiments the detecting is of an enzymatic activity or an immunological assay. In still other embodiments, the sqv nucleic acid molecule is selected from the group consisting of a sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6.

[0008] In another aspect, the invention features a screening method for identifying a compound that modulates the expression of a sqv nucleic acid molecule that encodes a polypeptide that has a glycosaminoglycan biosynthetic biological activity, the method involves (a) providing a cell containinga sqv nucleic acid molecule; (b) contacting the cell with a compound; and (c) detecting the level of nucleic acid molecule expression in the presence of the compound with the level of nucleic acid molecule expression in the absence of the compound; where an alteration in nucleic acid molecule expression indicates that the compound modulates the expression of a sqv nucleic acid molecule that encodes a polypeptide that has a glycosaminoglycan biosynthetic biological activity. In some embodiments, the sqv nucleic acid molecule is selected from the group consisting of a sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6. In other embodiments, the cell is a C. elegans cell. In preferred embodiments, the cell is a mammalian cell.

[0009] In another aspect, the invention features a screening method for identifying a compound that modulates the glycosaminoglycan biosynthetic biological activity of a SQV polypeptide, or fragment thereof, the method involves (a) providing a SQV polypeptide, or fragment thereof, where the polypeptide has a glycosaminoglycan biosynthetic biological activity; (b) contacting the polypeptide with a compound; and (c) detecting the level of biological activity of the polypeptide contacted with the compound with the level of biological activity in a polypeptide not contacted with the compound; where an alteration in the biological activity indicates that the compound modulates the glycosaminoglycan biosynthetic biological activity of a SQV polypeptide. In some embodiments, the polypeptide is in a mammalian cell. In other embodiments, the polypeptide is in a nematode cell. In preferred embodiments, the nematode cell is in a nematode and the detecting is of a vulval phenotype. In other preferred embodiments, the detecting is of an enzymatic activity. In preferred embodiments, the sqv nucleic acid molecule is selected from the group consisting of a sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6.

[0010] In another aspect, the invention features a screening method for identifying a compound that modulates the glycosaminoglycan biosynthetic biological activity of a SQV polypeptide, or fragment thereof, the method involves detecting binding of a candidate compound to a SQV polypeptide, where the detecting identifies the compound as a compound that modulates the glycosaminoglycan biosynthetic biological activity of a SQV polypeptide. In some embodiments, the sqv polypeptide is selected from the group consisting of SQV-1, SQV-2, SQV-4, SQV-5, and SQV-6.

[0011] In another aspect, the invention features a method of treating an organism having a connective tissue disease, progeroid disorder, or cellular damage related to aging the method involves (a) contacting the organism with a therapeutically effective amount of a nucleic acid encoding a SQV polypeptide, or the complement of the nucleic acid; and (b) detecting the expression of the nucleic acid; where the contacting modulates the level of expression of a SQV polypeptide. In preferred embodiments, the nucleic acid is a cDNA, and the contacting leads to an increase in expression of the polypeptide encoded by sqv nucleic acid molecule.

[0012] In another aspect, the invention features a method for diagnosing a connective tissue disease or progeroid disorder, or the propensity to develop the disease or disorder, the method involves detecting SQV polypeptide expression or activity in a sample derived from an organism relative to a sample derived from a control organism not having a connective tissue disease or progeroid disorder, where an alteration in the expression or activity of the SQV polypeptide in the organism is indicative of the organism's having or having a propensity to develop a connective tissue disease or progeroid disorder. In preferred embodiments, the SQV polypeptide is selected from the group consisting of SQV-1, SQV-2, SQV-4, SQV-5, and SQV-6.

[0013] In another aspect, the invention features a method for diagnosing a connective tissue disease or progeroid disorder or the propensity to develop the disease or disorder in an organism, where the method involves detecting the sequence of a sqv nucleic acid molecule in a sample derived from the organism relative to a wild-type nucleic acid sequence, where an alteration in the sequence of the organism is indicative of the organism having or having a propensity to develop a connective tissue disease or progeroid disorder. In some embodiments, the SQV nucleic acid molecule is selected from the group consisting of sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6.

[0014] In another aspect, the invention features a method for identifying a candidate compound for the treatment of a connective tissue disease, progeroid disorder, or the tissue damage associated with aging the method involves (a) contacting a SQV polypeptide with a candidate compound; and (b) detecting an alteration in the biological activity of the polypeptide. In some embodiments, the SQV polypeptide is selected from the group consisting of SQV-1, SQV-2, SQV-4, SQV-5, and SQV-6.

[0015] In another aspect, the invention features a pharmaceutical composition including a pharmaceutical excipient and a sqv nucleic acid molecule, or portion thereof, selected from the group consisting of sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6.

[0016] In another aspect, the invention features a pharmaceutical composition containing a pharmaceutical excipient and an RNA sqv nucleic acid inhibitor containing at least a portion of a sqv nucleic acid molecule of an organism, or its complement, selected from the group consisting of sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6.

[0017] In another aspect, the invention features a transgenic organism containing a sqv nucleic acid molecule, or complement thereof, that alters the function of a glycosaminoglycan biosynthetic biological activity in the organism. In preferred embodiments, the nucleic acid molecule is selected from the group consisting of sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6.

[0018] In another aspect, the invention features an isolated SQV-1 polypeptide, or fragment thereof, containing an amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 95%, or 100% amino acid sequence identity to SEQ ID NO: 4, where the polypeptide has a glycosaminoglycan biosynthetic biological activity. In some embodiments, the polypeptide contains the amino acid sequence of SEQ ID NO: 4. In other embodiments, the polypeptide consists essentially of the amino acid sequence of SEQ ID NO: 4, or a fragment thereof.

[0019] In another aspect, the invention features an isolated polypeptide fragment of SEQ ID NO: 4, where the fragment has a glycosaminoglycan biosynthetic biological activity.

[0020] In another aspect, the invention features an isolated SQV-1 polypeptide, or fragment thereof, containing an amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 95%, or 100% amino acid sequence identity to SEQ ID NO: 4, containinga mutation that inhibits the biological activity of the polypeptide. In some embodiments, the mutation corresponds to a mutation selected from the group consisting of n2820, n2824, n2828, n2848, ku246, and n2819. In some embodiments, the polypeptide contains the amino acid sequence of human SQV-1 (SEQ ID NO: 5). In other embodiments, the polypeptide consists essentially of the amino acid sequence of human SQV-1 (SEQ ID NO: 5), or a fragment thereof. In still other embodiments, the polypeptide contains the amino acid sequence of Drosophila SQV-1 (SEQ ID NO: 6). In still other embodiments, polypeptide consists essentially of the amino acid sequence of Drosophila SQV-1 (SEQ ID NO: 6), or a fragment thereof.

[0021] In another aspect, the invention features an isolated sqv-1nucleic acid molecule, or fragment thereof, that encodes a polypeptide sequence having 50%, 60%, 70%, 80%, 90%, 95%, or 100% amino acid sequence identity to SEQ ID NO: 4, where the polypeptide has a glycosaminoglycan biosynthetic biological activity. In other embodiments, nucleic acid molecule contains the nucleotide sequence of SEQ ID NO: 2, or a complement thereof. In still other embodiments, nucleic acid molecule consists essentially of the nucleotide sequence of SEQ ID NO: 2, or a fragment thereof. In still other embodiments, nucleic acid molecule encodes the amino acid sequence of human SQV-1 (SEQ ID NO: 5). In still other embodiments, nucleic acid molecule consists essentially of the nucleic acid sequence of human SQV-1 (SEQ ID NO: 3), or a fragment thereof. In still other embodiments, the nucleic acid contains a mutation that corresponds to a mutation selected from the group consisting of n2820, n2824, n2828, n2848, ku246, and n2819.

[0022] In another aspect, the invention features an isolated nucleic acid molecule that hybridizes under high stringency conditions to SEQ ID NO: 2.

[0023] In another aspect, the invention features an isolated nucleic acid molecule that hybridizes under high stringency conditions to SEQ ID NO: 5.

[0024] In another aspect, the invention features an isolated sqv-1nucleic acid, regardless of length, complementary to at least a portion of SEQ ID NO: 5, capable of decreasing the expression of a SQV-1 polypeptide. In other embodiments, the nucleic acid is a dsRNA, antisense RNA, or siRNA.

[0025] In another aspect, the invention features an isolated SQV-2 polypeptide, or fragment thereof, containing an amino acid sequence having at least 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 10, where the polypeptide has a glycosaminoglycan biosynthetic biological activity. In other embodiments, polypeptide contains the amino acid sequence SEQ ID NO: 10. In other embodiments, polypeptide consists essentially of the amino acid sequence SEQ ID NO: 10, or a fragment thereof.

[0026] In another aspect, the invention features an isolated polypeptide fragment of SEQ ID NO: 10, where expression of the fragment has a glycosaminoglycan biosynthetic biological activity.

[0027] In another aspect, the invention features an isolated SQV-2 polypeptide, or fragment thereof, containing an amino acid sequence having at least 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 10, and containinga mutation that inhibits the biological activity of the polypeptide. In some embodiments, the mutation corresponds to the mutation in n3037 or n3038. In other embodiments, polypeptide contains the amino acid sequence of human SQV-2 (SEQ ID NO: 12). In yet other embodiments, polypeptide consists essentially of the amino acid sequence of human SQV-2 (SEQ ID NO: 12), or a fragment thereof. In some embodiments, the polypeptide contains the amino acid sequence of Drosophila SQV-2 (SEQ ID NO: 11). In other embodiments, polypeptide consists essentially of the amino acid sequence of Drosophila SQV-2 (SEQ ID NO: 11), or a fragment thereof.

[0028] In another aspect, the invention features an isolated sqv-2 nucleic acid molecule, or fragment thereof, that encodes a polypeptide sequence having 25%, 28%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 10, where expression of the nucleic acid molecule has a glycosaminoglycan biosynthetic biological activity. In some embodiments, the isolated nucleic acid molecule contains the nucleotide sequence of SEQ ID NO: 8, or a complement thereof. In some embodiments, the isolated nucleic acid molecule consists essentially of the nucleotide sequence of SEQ ID NO: 8, or a fragment thereof. In other embodiments, the nucleic acid molecule encodes the amino acid sequence of human SQV-2 (SEQ ID NO: 12). In other embodiments, the nucleic acid molecule consists essentially of the nucleic acid sequence of human SQV-2 (SEQ ID NO: 9), or a fragment thereof. In some embodiments, the sqv-2 nucleic acid molecule further contains a mutation corresponding to the mutation in sqv-2 allele n3037 or n3038 that inhibits the biological activity of the polypeptide.

[0029] In another aspect, the invention features an isolated nucleic acid molecule that hybridizes under high stringency conditions to SEQ ID NO: 8.

[0030] In another aspect, the invention features an isolated nucleic acid molecule that hybridizes under high stringency conditions to SEQ ID NO: 9.

[0031] In another aspect, the invention features an isolated sqv-2 nucleic acid, regardless of length, complementary to at least a portion of the nucleic acid sequence capable of decreasing the expression of a SQV-2 polypeptide. In some embodiments, the nucleic acid is a dsRNA, antisense RNA, or siRNA.

[0032] In another aspect, the invention features an isolated SQV-5 polypeptide, or fragment thereof, containing an amino acid sequence having at least 25%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 24, where the polypeptide has a glycosaminoglycan biosynthetic biological activity. In some embodiments, the polypeptide contains the amino acid sequence SEQ ID NO: 24. In other embodiments, the polypeptide consists essentially of the amino acid sequence SEQ ID NO: 24, or a fragment thereof

[0033] In another aspect, the invention features an isolated polypeptide fragment of SEQ ID NO: 24, where the fragment has a glycosaminoglycan biosynthetic biological activity.

[0034] In another aspect, the invention features an isolated SQV-5 polypeptide, or fragment thereof, containing an amino acid sequence having at least 35%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 24, and further contains a mutation that inhibits the biological activity of the polypeptide. In some embodiments, the polypeptide further contains a mutation that corresponds to sqv-5 (n3039) and inhibits the biological activity of the polypeptide. In other embodiments, the polypeptide contains the amino acid sequence of human SQV-5 (SEQ ID NO: 25). In some embodiments, the polypeptide consists essentially of the amino acid sequence of human SQV-5 (SEQ ID NO: 25), or a fragment thereof. In other embodiments, the substantially pure polypeptide is substantially identical to the Drosophila amino acid sequence of SEQ ID NO: 26.

[0035] In another aspect, the invention features a substantially pure polypeptide that contains the Drosophila amino acid sequence of SEQ ID NO: 26. In some embodiments, the isolated sqv-5 nucleic acid molecule, or fragment thereof, that encodes a polypeptide sequence having 38%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 24, where the nucleic acid molecule has a glycosaminoglycan biosynthetic biological activity. In other embodiments, the isolated nucleic acid molecule contains the nucleotide sequence of SEQ ID NO: 28 or a complement thereof. In other embodiments, the isolated nucleic acid molecule consists essentially of the nucleotide sequence of SEQ ID NO: 28 or a fragment thereof. In some embodiments, the isolated nucleic acid molecule further contains a mutation that corresponds to the mutation identified in sqv-5 (n3039) or n3611.

[0036] In another aspect, the invention features an isolated nucleic acid molecule that hybridizes under high stringency conditions to SEQ ID NO: 8.

[0037] In another aspect, the invention features an isolated nucleic acid molecule that hybridizes under high stringency conditions to SEQ ID NO: 9.

[0038] In another aspect, the invention features a sqv-5 nucleic acid, regardless of length, that contains the nucleic acid sequence, or a complement thereof, and decreases the expression of a SQV-5 polypeptide. In some embodiments, the nucleic acid is a dsRNA, antisense RNA, or siRNA.

[0039] In another aspect, the invention features an isolated SQV-4 polypeptide, or fragment thereof, containing an amino acid sequence having at least 65%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 20, where the polypeptide has a glycosaminoglycan biosynthetic biological activity. In some embodiments, the polypeptide contains the amino acid sequence SEQ ID NO: 20. In other embodiments, the polypeptide consists essentially of the amino acid sequence SEQ ID NO: 20, or a fragment thereof.

[0040] In another aspect, the invention features an isolated SQV-4 polypeptide, or fragment thereof, containing an amino acid sequence having at least 65%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 20, where the polypeptide has a glycosaminoglycan biosynthetic biological activity.

[0041] In another aspect, the invention features an isolated SQV-4 polypeptide, or fragment thereof, containing an amino acid sequence having at least 65%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 20, where the polypeptide further contains a mutation that inhibits the biological activity of the polypeptide. In some embodiments, the mutation corresponds to the mutation identified in sqv-4 (n2827) or (n2840).

[0042] In another aspect, the invention features an isolated sqv-4 nucleic acid molecule, or fragment thereof, that encodes a polypeptide sequence having at least 65%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 20, where the nucleic acid molecule has a glycosaminoglycan biosynthetic biological activity. In some embodiments, the isolated nucleic acid molecule contains the nucleotide sequence of SEQ ID NO: 18, or a complement thereof. In some embodiments, the isolated nucleic acid molecule consists essentially of the nucleotide sequence of SEQ ID NO: 18, or a fragment thereof.

[0043] In another aspect, the invention features an isolated sqv-4 nucleic acid molecule, or fragment thereof, that encodes a polypeptide sequence having at least 65%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 20, where the nucleic acid molecule contains a mutation that inhibits the biological activity of an encoded polypeptide. In some embodiments, the mutation corresponds to the mutation identified in sqv-4 allele n2827 or n2840.

[0044] In another aspect, the invention features an isolated SQV-6 polypeptide, or fragment thereof, containing an amino acid sequence having at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 15, where the polypeptide has a glycosaminoglycan biosynthetic biological activity. In some embodiments, the polypeptide contains the amino acid sequence SEQ ID NO: 15. In other embodiments, the polypeptide consists essentially of the amino acid sequence SEQ ID NO: 15, or a fragment thereof.

[0045] In another aspect, the invention features an isolated polypeptide fragment of SEQ ID NO: 15, where the fragment has a glycosaminoglycan biosynthetic biological activity.

[0046] In another aspect, the invention features an isolated SQV-6 polypeptide, or fragment thereof, containing an amino acid sequence having at least 30% amino acid sequence identity to SEQ ID NO: 15, where the polypeptide further contains a mutation that inhibits the biological activity of the polypeptide. In some embodiments, the mutation corresponds to the mutation identified in sqv-6 (n2845).

[0047] In another aspect, the invention features an isolated sqv-6 nucleic acid molecule, or fragment thereof, that encodes a polypeptide sequence having at least 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 15, where the nucleic acid molecule has a glycosaminoglycan biosynthetic biological activity. In some embodiments, the isolated nucleic acid molecule contains the nucleotide sequence of SEQ ID NO: 14, or a complement thereof. In some embodiments, the isolated nucleic acid molecule consists essentially of the nucleotide sequence of SEQ ID NO: 14, or a fragment thereof.

[0048] In another aspect, the invention features an isolated sqv-6 nucleic acid molecule, or fragment thereof, that encodes a polypeptide sequence having at least 30% amino acid sequence identity to SEQ ID NO: 15, where the nucleic acid molecule contains a mutation that corresponds to the mutation identified in sqv-6 allele n2845 that inhibits the biological activity of an encoded polypeptide.

[0049] In another aspect, the invention features a sqv-6 nucleic acid molecule, regardless of length, that contains the nucleic acid sequence of SEQ ID NO: 13, or a complement thereof, and decreases the expression of a SQV-6 polypeptide. In some embodiments, the nucleic acid molecule is a dsRNA, antisense RNA, or siRNA.

[0050] By “antisense” is meant a nucleic acid sequence, regardless of length or particular backbone chemistry, that is complementary to the coding strand or mRNA of a gene. Preferably, the antisense nucleic acid is capable of decreasing mRNA levels of a mammalian or C. elegans sqv gene and/or altering a GAG pathway. Preferably the alteration is at least 10%, relative to a control, more preferably 25%, 30%, 40%, or 50%, and most preferably 60%, 70%, 80%, 90%, or more. Preferably, a sqv antisense nucleic acid molecule includes 8, 10, 15, 20, 25, or 30 nucleotides. A sqv antisense nucleic acid molecule may also contain at least 40, 60, 85, 120, or more consecutive nucleotides that are complementary to a sqv mRNA or cDNA, and may be as long as a full-length sqv gene or mRNA. The antisense nucleic acid may contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or other modified backbones known in the art, or may contain non-natural internucleoside linkages.

[0051] By “biological activity” is meant any naturally occurring activity of a nucleic acid molecule or polypeptide in the organism from which it is derived. For example, by a SQV biological activity is meant any activity that contributes to the production of a glycosaminoglycan, including any activity of a SQV nucleic acid or polypeptide of the invention (e.g., a UDP-glucuronic acid decarboxylase, GAG galactosyltransferase II, UDP-glucose dehydrogenase, chondroitin synthase, or GAG xylosyltransferase activity).

[0052] By “derived from” is meant isolated from or having the sequence of a naturally-occurring sequence (e.g., a cDNA, genomic DNA, synthetic, or combination thereof).

[0053] By “high stringency conditions” is meant conditions that allow hybridization comparable with the hybridization that occurs using a DNA probe of at least 300, 400, or 500 nucleotides in length, in a buffer containing 0.5 M NaHPO4, pH 7.2, 7% SDS, 1 mM EDTA, and 1% BSA (fraction V), at a temperature of 65° C., or a buffer containing 48% formamide, 4.8×SSC, 0.2 M Tris-Cl, pH 7.6, 1×Denhardt's solution, 10% dextran sulfate, and 0.1% SDS, at a temperature of 42° C. (These are typical conditions for high stringency northern or Southern hybridizations.) High stringency hybridization is also relied upon for the success of numerous techniques routinely performed by molecular biologists, such as high stringency PCR, DNA sequencing, single strand conformational polymorphism analysis, and in situ hybridization. In contrast to Northern and Southern hybridizations, these techniques are usually performed with relatively short probes (e.g., usually 16 nucleotides or longer for PCR or sequencing, and 40 nucleotides or longer for in situ hybridization). The high stringency conditions used in these techniques are well known to those skilled in the art of molecular biology, and examples of them can be found, for example, in Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience, New York, 2000, which is hereby incorporated by reference.

[0054] By “inhibits” is meant to decrease. For example, a nucleic acid molecule, compound, polypeptide or other agent that inhibits the expression or activity of a composition of the invention, decreases the activity or expression by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.

[0055] By “enhance” is meant increase. For example, a nucleic acid molecule, compound, polypeptide or other agent that enhances the expression or activity of a composition of the invention, increases the activity or expression by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.

[0056] By “fragment” is meant at least a portion of the full length nucleic acid or polypeptide molecule that has 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or even 100% sequence identity to a reference nucleic acid molecule or polypeptide; that binds an antibody that specifically binds to the polypeptide from which the fragment is derived; or that includes a conserved domain required for biological activity. Domains required for biological activity typically share a high degree of sequence identity (e.g., 70%, 80%, 90%, 95%, or 100% within a particular domain) with a reference nucleic acid or polypeptide. In addition, domains required for biological activity may be identified by the presence of a mutation that inhibits the biological activity of the reference polypeptide. The presence of such mutations in a particular protein domain or region identifies that domain or region as functionally important. Fragments may have as few as 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 amino acids or nucleotides. Fragments may have as many as 150, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 amino acids or nucleotides.

[0057] By “isolated nucleic acid molecule” is meant a nucleic acid (e.g., a DNA) that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule which is transcribed from a DNA molecule, as well as a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

[0058] By “isolated polypeptide” is meant a polypeptide of the invention that has been separated from components which naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, a polypeptide of the invention. An isolated polypeptide of the invention may be obtained, for example, by extraction from a natural source (for example, a cell or cell extract); by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.

[0059] By “polypeptide” is meant any chain of amino acids, regardless of length or post-translational modification (for example, glycosylation or phosphorylation). By “positioned for expression” is meant that the DNA molecule is positioned adjacent to a DNA sequence which directs transcription and translation of the sequence (i.e., facilitates the production of, for example, a recombinant polypeptide of the invention, or an RNA molecule).

[0060] By “purified antibody” is meant an antibody which is at least 60%, by weight, free from proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably 90%, and most preferably at least 99%, by weight, antibody. A purified antibody of the invention may be obtained, for example, by affinity chromatography using a recombinantly-produced polypeptide of the invention and standard techniques.

[0061] By “specifically binds” is meant a compound or antibody which recognizes and binds a polypeptide of the invention, but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a polypeptide of the invention.

[0062] By “substantially identical” is meant a polypeptide or nucleic acid molecule exhibiting at least 30% identity to a reference amino acid sequence (e.g., a polypeptide encoded by sqv-1, sqv-2, sqv-4, sqv-5, or sqv-6) or nucleic acid sequence. Preferably, such a sequence is at least 30%, 40%, 50%, 60%, 70%, more preferably 80% or 85%, and most preferably 90% or even 95% identical at the amino acid or nucleic acid level to the reference sequence used for comparison.

[0063] Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e−3 and e−100 indicating a closely related sequence.

[0064] By “transformed cell” is meant a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding (as used herein) a polypeptide of the invention.

[0065] By “sample” is meant a tissue biopsy, amniotic fluid, cell, blood, serum, urine, stool, or other specimen obtained from a patient or a test subject. The sample can be analyzed to detect a mutation in a sqv-1, sqv-2, sqv-4, sqv-5, or sqv-6 nucleic acid sequence using methods that are known in the art. For example, methods such as sequencing, single-strand conformational polymorphism (SSCP) analysis, or restriction fragment length polymorphism (RFLP) analysis of PCR products derived from a patient sample can be used to detect a mutation in a sqv-1, sqv-2, sqv-4, sqv-5, or sqv-6 nucleic acid molecule.

[0066] By a “SQV polypeptide” is meant a SQV amino acid molecule, or fragment thereof, substantially identical to, and having the biological activity of a SQV polypeptide of the invention, for example, the activity of SQV-1, SQV-2, SQV-4, SQV-5, or SQV-6 polypeptide, or a polypeptide that functions in a pathway. Specifically excluded by this definition is the biological activity of a SQV-3, SQV-7, or SQV-8 polypeptide.

[0067] By “sqv gene” is meant a sqv nucleic acid sequence that encodes a SQV polypeptide, for example, a polypeptide, or fragment thereof, substantially identical to the SQV amino acid sequence provided in FIG. 2, 10, 12A, 14, or 25. Specifically excluded by this definition are sqv-3, sqv-7, or sqv-8.

[0068] By “SQV-1 biological activity” is meant any activity of a SQV-1 polypeptide of FIG. 2, such as an enzymatic activity (e.g., that of a GAG biosynthetic enzyme or that of a UDP-glucuronic acid decarboxylase). Such an activity can be assayed, for example, by an assay for decarboxylase activity as described at page 20.

[0069] By “SQV-1 polypeptide” is meant a polypeptide or fragment thereof, having SQV-1 biological activity and substantially identical to a SQV-1 polypeptide sequence, for example, a polypeptide that is at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, or even 99% identical to a human, Drosophila, or nematode SQV-1 amino acid sequence provided in FIG. 2.

[0070] By “sqv-1” is meant a sqv-1 nucleic acid sequence that encodes a SQV-1 polypeptide, for example, a polypeptide, or fragment thereof, substantially identical to a SQV-1 amino acid sequence provided in FIG. 2.

[0071] By “SQV-2 biological activity is, meant any activity of a SQV-2 polypeptide of FIG. 10, such as an enzymatic activity (e.g., that of a GAG biosynthetic enzyme or GAG galactosyltransferase II). Such an activity can be assayed, for example, in a GAG galactosyltransferase II assay, as described by Bai et al. (J. Biol. Chem. 276:189-95, 2001).

[0072] By “SQV-2 polypeptide” is meant a polypeptide, or fragment thereof, substantially identical to and having the biological activity of SQV-2 polypeptide, for example, a polypeptide that is at least 40%, 45%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or even 99% identical to a human, Drosophila, or nematode to SQV-2 amino acid sequence provided in FIG. 10.

[0073] By “sqv-2” is meant a sqv-2 nucleic acid sequence that encodes a SQV-2 polypeptide, for example, a polypeptide substantially identical to a SQV-2 amino acid sequence provided in FIG. 10.

[0074] By “sqv-4” is meant a sqv-4 nucleic acid sequence that encodes a SQV-4 polypeptide, for example, a polypeptide substantially identical to a SQV-4 amino acid sequence provided in FIG. 14.

[0075] By “SQV-4 biological activity” is meant any activity of the SQV-4 polypeptide of FIG. 14, such as an enzymatic activity (e.g., that of a GAG biosynthetic enzyme or UDP-glucose dehydrogenase). Such an activity may be assayed, for example, in an assay for a UDP-glucose dehydrogenase activity (Strominger et al., J. Amer. Chem. Soc. 76:6411-6412, 1954; Hempel et al., Protein Science 3:1074-1080, 1994).

[0076] By “SQV-4 polypeptide” is meant a polypeptide, or fragment thereof, having SQV-4 biological activity and substantially identical to a SQV-4 amino acid sequence, for example, a polypeptide that is at least 75%, 80%, 85%, 90%, or 95% identical to a human, Drosophila, Arabidopsis, or nematode SQV-4 amino acid sequence provided in FIG. 14.

[0077] By “sqv-5” is meant a sqv-5 nucleic acid sequence that encodes a SQV-5 polypeptide, for example, a polypeptide substantially identical to a SQV-5 amino acid sequence provided in FIG. 25.

[0078] By “SQV-5 biological activity” is meant any activity of a SQV-5 nematode, Drosophila or human polypeptide of FIG. 25, for example, an enzymatic activity (e.g., that of GAG biosynthetic enzyme or chondroitin synthase). Such an activity may be assayed, for example, as described by DeAngelis et al. (J. Biol. Chem. 27:24124-24129, 2000).

[0079] By “SQV-5 polypeptide” is meant a polypeptide having SQV-5 biological activity and substantially identical to a SQV-5 amino acid sequence of FIG. 25, for example, a polypeptide that is at least 35%, 38%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% identical to a human, Drosophila, or nematode SQV-5 amino acid sequence provided in FIG. 25.

[0080] By “sqv-6” is meant a sqv-6 nucleic acid sequence that encodes a SQV-6 polypeptide, for example, a polypeptide substantially identical to a human or nematode SQV-6 amino acid sequence provided in FIG. 12A.

[0081] By “SQV-6 biological activity” is meant any activity of a SQV-6 polypeptide of FIG. 12A, such as an enzymatic activity (e.g., that of GAG biosynthetic enzyme or a GAG xylosyltransferase). Such an activity may be assayed, for example, in a GAG xylosyltransferase activity assay, as described by Esko et al. (Proc. Natl. Acad. Sci. 82:3197-201).

[0082] By “SQV-6 polypeptide” is meant a polypeptide that has SQV-6 biological activity or is substantially identical to a SQV-6 polypeptide sequence, for example, a polypeptide that is at least 50%, 60%, 75%, 80%, 85%, 90%, or 95% identical to the SQV-6 amino acid sequence provided in FIG. 12A.

BRIEF DESCRIPTION OF THE DRAWINGS

[0083] FIG. 1A is a diagram showing genetic and physical maps of the sqv-1 region. The horizontal lines at the top of the panel indicate the extent of a chromosomal deletion in deficiencies eDf18 and eDf19. Dashed horizontal lines depicting eDf18 and eDf19 indicate the possible extent of the left end points of eDf18 and eDf19. These endpoints are described relative to a series of cosmids that contain virtually the entire C. elegans genome. These endpoints are between cosmids B0218 and F35H10, for eDf19, and between cosmids C07G1/T09A12 and F35H10, for eDf18. Short solid horizontal lines represent cosmid clones that were assayed in germline transformation experiments (cosmids B0218 and C07G1 were not tested). The parallel vertical lines represent a gap in cosmid coverage of the C. elegans genome. The D2096 cosmid that rescued the sqv-1 mutant phenotype is shown in bold.

[0084] FIG. 1B is a diagram showing the D2096 cosmid subclones that were tested for sqv-1rescuing activity. Subclones that rescued the sqv-1mutant phenotype are shown in bold. The rescue results are expressed as the number of transformed lines that rescued/total number of lines tested. At the bottom of the panel is a schematic diagram showing the structure and location of the sqv-1 gene as deduced from the genomic and cDNA sequences relative to the minimal rescuing subclone. Solid boxes indicate exons, and open boxes indicate untranslated sequences. The sqv-1 5′ trans-spliced leader, SL1, is indicated, and the arrow indicates the sqv-1 3′ poly(A) tail. The extent of the deletion in sqv-1(n3790) is indicated by a horizontal line.

[0085] FIG. 1C shows the C. elegans sqv-1 genomic sequence (D2096.1) (SEQ ID NO: 1) aligned with the sqv-1 cDNA (SEQ ID NO: 2). The start and stop codons are indicated in bold.

[0086] FIG. 1D shows the nucleic acid sequence of human sqv-1 (SEQ ID NO: 3).

[0087] FIG. 2 shows an amino acid sequence alignment of C. elegans SQV-1 (SEQ ID NO: 4), SQV-1 Human (SEQ ID NO: 5), and Drosophila (SEQ ID NO: 6) homologs. The numbers on the right indicate amino acid positions. Identities shared by at least two polypeptides are shaded in black. The missense mutations for the sqv-1 mutant alleles are indicated. The putative transmembrane domains are underlined.

[0088] FIG. 3A is a UV trace of extracted ion chromatography (XIC) of mass of 500 to 700 from the SQV-1 reaction. It shows the negative polarity mass spectra of SQV-1 reaction sample. The y-axis indicates the intensity of the spectra, and the x-axis indicates the mass (mass to charge ratio (m/z)). Peaks of mass (m/z) of 500 to 600 are shown.

[0089] FIG. 3B shows the magnification of mass spectra for mass (m/z) of 530 to 540. The highest peak at ˜535 represents the most abundant mass of UDP-xylose. Smaller peaks at ˜536 and ˜537 represent isotopic masses of UDP-xylose containing heavy isotopes of carbon, hydrogen, oxygen or nitrogen.

[0090] FIG. 4A is a photomicrograph showing anti-SQV-1 antibody staining of oocytes. The three most mature oocytes (oocy), including the most proximal oocyte (prox oocy), are indicated. The oocytes were prepared in a whole-mount staining of wild-type nematodes using an anti-SQV-1-myelin basic protein (MBP) rabbit polyclonal antibodies. SQV-1 antibodies localized to punctate cytoplasmic foci.

[0091] FIG. 4B is a photomicrograph showing anti-SQV-1 antibody staining of coelomocytes (coel) in an L4 larva. Coelomocytes are indicated by a white arrow.

[0092] FIGS. 4C and 4D are photomicrographs showing anti-SQV-1 antibody staining of vulval cells (v) during vulval morphogenesis in two different focal planes. The location of vulval cells is indicated by brackets. The inset indicates the boundaries of the vulval cells.

[0093] FIG. 5A is a photomicrograph showing SQV-7 staining in oocytes. The four most mature oocytes (oocy), including the most proximal oocyte (prox oocy), are indicated. The oocytes were prepared in whole-mount staining of wild-type nematodes using anti-SQV-7 peptide antibodies. SQV-7 antibodies localized to punctate cytoplasmic foci.

[0094] FIG. 5B is a photomicrograph showing SQV-7 staining in seam cells (seam) and the distal tip cell (DTC) in an L4 larva. Seam cells line the length of the worm from head to tail. The distal tip cell is located at the end of the migrating gonad, which is to the left of the DTC in this image.

[0095] FIG. 5C is a photomicrograph showing SQV-7 staining in the vulval precursor cells (VPCs) in an L3 larva. Twelve VPCs are indicated by arrows. Ten of the twelve VPCs will divide once more to generate the twenty-two vulval cells that form the vulva.

[0096] FIG. 5D is a photomicrograph showing SQV-7 staining in vulval cells (v) during vulval morphogenesis in an L4 larva. A subset of the twenty-two vulval cells is visible in this focal plane.

[0097] FIG. 5E is a diagram showing the structure of the sqv-7 gene using solid boxes to indicate exons. The initiation and termination codons are indicated. The sqv-7(n3789) deletion allele is shown using a thin solid line to depict the extent of the deletion.

[0098] FIG. 6A is a photomicrograph showing SQV-7 staining of oocytes. Anti-SQV-7 rabbit peptide antibody staining was visualized using Texas Red-conjugated secondary antibodies.

[0099] FIG. 6B is a photomicrograph showing SQV-1 staining of the same oocytes shown in FIG. 6A. SQV-1-MBP rat antibody staining was visualized by FITC-conjugated secondary antibodies.

[0100] FIG. 6C is a photomicrograph showing a merged image of FIGS. 6A and 6B. SQV-1 and SQV-7 colocalized in oocytes.

[0101] FIGS. 7A-7C are Nomarski photomicrographs of early embryogenesis in a wild-type embryo.

[0102] FIGS. 7D-7F are Nomarski photomicrographs of a sqv-7(n3789) mutant embryo.

[0103] FIGS. 7A and 7D are Nomarski photomicrographs showing fertilized wild-type and sqv-7 null embryos, respectively

[0104] FIGS. 7B and 7E are Nomarski photomicrographs showing the appearance of egg (o) and sperm (s) pronuclei in wild-type and sqv-7 null embryos, respectively, after fertilization. Constriction of the plasma membrane, or pseudocleavage, is indicated by arrows in the wild-type embryo.

[0105] FIGS. 7C and 7F are Nomarski photomicrographs showing the pronuclear meeting in wild-type and sqv-7 null embryos, respectively. A polar body (p) is indicated in the wild-type embryo. The space between the plasma membrane and eggshell is indicated by a bracket in the wild-type embryo.

[0106] FIGS. 8A-8C are Nomarski photomicrographs of early embryogenesis in a wild-type embryo.

[0107] FIGS. 8D-8F are Nomarski photomicrographs of a sqv-7(n3789) mutant embryo.

[0108] FIGS. 8A and 8D are Nomarski photomicrographs showing the rotation of the mitotic spindle onto the anterior-posterior axis in wild-type and sqv-7 null embryos, respectively. The space between the plasma membrane and the eggshell in the wild-type embryo is indicated by a bracket.

[0109] FIGS. 8B and 8E are Nomarski photomicrographs showing the first mitosis in wild-type and sqv-7 null embryos, respectively. The initiation of cytokinesis is visible in the wild-type embryo, but not in the sqv-7 mutant embryo. The constriction of the plasma membrane in the wild-type embryo is indicated by arrows.

[0110] FIGS. 8C and 8F are Nomarski photomicrographs showing embryos after the first nuclear division in wild-type and sqv-7 null embryos, respectively. The wild-type embryo is a two-cell embryo with the daughter cells labeled (AB, P0). The sqv-7 mutant embryo contains more than two nuclei in a single cytoplasm. Multiple nuclei present in the sqv-7 mutant embryo are indicated by arrows.

[0111] FIG. 9A shows the genetic and physical map of sqv-2. The dashed horizontal lines depicting deficiencies ccDf11 and ccDf1 indicate the possible extent of the left end points of these deletions. Short solid lines represent cosmid clones that were assayed in germline transformation experiments.

[0112] FIG. 9B shows the structure of the sqv-2 gene. Solid boxes indicate exons, and open boxes indicate untranslated sequences. The sqv-2 trans-spliced leader SL1 is indicated, and the arrow indicates the sqv-2 poly(A) tail.

[0113] FIG. 9C shows an alignment of the C. elegans sqv-2 genomic (Y 110A2AL.1) (SEQ ID NO: 7) and cDNA (SEQ ID NO: 8) nucleic acid sequences. The start and stop codons are indicated in bold.

[0114] FIG. 9D shows the nucleic acid sequence of the human sqv-2 homolog (SEQ ID NO: 9).

[0115] FIG. 10 shows the alignment of SQV-2 (SEQ ID NO: 10), a Drosophila homolog (SEQ ID NO: 11), and human GAG galactosyltransferase II (SEQ ID NO: 12). Identities between two or more proteins are shaded in black. The predicted transmembrane domains are underlined. The three sqv-2 mutant alleles are indicated. The numbers on the right indicate amino acid positions.

[0116] FIG. 11A shows the genetic and physical map of sqv-6. Short solid lines represent cosmid clones that were assayed in germline transformation experiments.

[0117] FIG. 11B shows the structure of the sqv-6 gene. Solid boxes indicate exons. The sqv-6 trans-spliced leader SLI and the sqv-6 start codon (ATG) are indicated.

[0118] FIG. 11C shows the nucleic acid sequence of C. elegans sqv-6 (SEQ ID NO: 13) and cDNA sequences (SEQ ID NO: 14). The start and stop codons are indicated.

[0119] FIG. 12A shows an alignment of SQV-6 (SEQ ID NO: 15)and two human GAG xylosyltranferases (SEQ ID NOS: 16 and 17). Identities between two or more proteins are shaded in black. The predicted transmembrane domains are underlined. The single sqv-6 nonsense allele is indicated. The numbers on the right indicate amino acid positions.

[0120] FIG. 12B is a bar graph showing, on the y axis, the average 35S incorporation (cpm/μg protein) and on the x axis, trials at various temperatures in wild-type CHO-K1 cells, xylosyltransferase deficient mutant pgsA-745 cells, xylosyltransferase deficient mutant pgsA-745 cells transfected with an empty vector, and xylosyltransferase deficient mutant pgsA-745 cells transfected with wild-type sqv-6.

[0121] FIG. 13A shows the genetic and physical maps of the sqv-4 locus. The dashed horizontal line depicting deficiency sDf35 indicates the possible extent of the right end point of this deletion, between C35A5 and T21C9 (T21C9 is not shown.). The short solid horizontal lines represent cosmid clones that were assayed in germline transformation experiments. Overlapping cosmids C49D6 and H27A22 were assayed instead of T21 C9. The parallel vertical lines indicate a gap in the cosmid coverage of the C. elegans genome. Cosmids that rescued the sqv-4 mutant phenotype are shown in bold.

[0122] FIG. 13B shows subclones derived from the cosmids C32C4 and C04G9 that correspond to the common region shared by the two cosmids. Subdlones that rescued the sqv-4 mutant phenotype are shown in bold. The rescue data are shown as the number of transformed lines that rescued/total number of lines tested.

[0123] FIG. 13C shows the structure of the sqv-4 gene. Solid boxes indicate exons, and open boxes indicate untranslated sequences. The sqv-4 trans-spliced leader SLI is indicated, and the arrow indicates the sqv-4 poly(A) tail.

[0124] FIG. 13D shows the nucleic acid sequence of C. elegans sqv-4 (SEQ ID NO: 18) and genomic nucleic acid molecules (SEQ ID NO: 19). Start and stop codons are indicated.

[0125] FIG. 14 shows the sequence alignmnent of C. elegans SQV-4 (SEQ ID NO: 20) Drosophila melanogaster (Sugarless) (SEQ ID NO: 21), human (SEQ ID NO: 22), and Arabidopsis thaliana (SEQ ID NO: 23) UDP-glucose dehydrogenases. The numbers on the right indicate amino acid positions. Amino acid identities between two (or more) proteins are shaded in black or gray. The positions of the two sqv-4 missense alleles are indicated.

[0126] FIG. 15A is a diagram of the UDP-glucose dehydrogenase reaction. Two molecules of AND+ are reduced to NADH as one molecule of uridine diphosphate (UDP)-glucose and one molecule of water are converted to one molecule of UDP-glucuronic acid.

[0127] FIG. 15B shows the progress of the UDP-glucose dehydrogenase reaction as measured by AND+ reduction at 340 nm. Reaction curves of wild-type, SQV-4 T2A (SQV-4 T2A contains a threonine-to-alanine substitution at the second amino acid position that was caused by the addition of an NcoI restriction site at the 5′ end of the sqv-4 ORF), and mutant SQV-4 (R353H) (SQV-4 (R353H) contains the same mutation as the n2827 mutant allele) are shown. Approximately 3 mg of a soluble protein fraction containing SQV-4 was mixed with 50 μM UDP-glucose and 50 μM AND+. Absorbance at 340 nm was measured at one second intervals for 100 seconds.

[0128] FIG. 16A shows a double-reciprocal plot of the initial reaction velocities with UDP-glucose as the variable substrate. Initial velocity was measured using the linear phase of the reaction curve (20 to 30 second intervals). AND+ concentrations were 25 μM, 50 μM, or 100 μM.

[0129] FIG. 16B shows a double reciprocal plot of the initial reaction velocities with AND+ as the variable substrate. Initial velocity was measured using the linear phase of the reaction curve (20 to 30 second intervals). UDP-glucose concentrations were 25 μM, 50 μM, or 100 μM. Km values were calculated by the method of Lineweaver and Burke (1934).

[0130] FIG. 17 shows Western blots probed with anti-SQV-4 antibodies raised from two different rabbits (Ab A and Ab B). The Anti-SQV-4 antibodies detected a protein of the expected size (53 kDa) in a wild-type protein extract. The molecular weights (kDa) of SDS-PAGE standard markers (Bio-Rad, Hercules, Calif.) are indicated. The protein of approximately 95 kDa is probably of bacterial origin, since a protein of the same size is detected in an immunoblot of proteins from E. coli.

[0131] FIG. 18 is a photomicrograph showing anti-SQV-4 antibody staining in a row of oocytes in an adult hermaphrodite. This staining was absent in animals stained with pre-immune sera or antibodies that were pre-absorbed with GST-SQV-4. The oocyte most proximal to the uterus is located at the lower left.

[0132] FIGS. 19A-19C are confocal images showing that anti-SQV-4 antibodies stained a subset of vulval cells during early vulval morphogenesis.

[0133] FIGS. 20A and 20B are confocal images showing anti-SQV-4 antibody staining in vulval cells during later vulval morphogenesis.

[0134] FIG. 20A shows vulval cells containing four nuclei (P5.ppal, P6.paal, P6.pppl and P7.papl) on the left side of the worm.

[0135] FIG. 20B shows SQV-4 antibody staining in vulval cells containing two of the four dorsal-most nuclei (P6.papl and P6.ppal), which were not stained at an earlier stage.

[0136] FIG. 20C is a confocal image showing anti-SQV-4 antibody staining during later vulval morphogenesis in two vulval cells (P5.ppp and P7.paa) in the middle plane of the worm.

[0137] FIG. 20D shows anti-SQV-4 antibody staining in vulval cells containing two of the four dorsal-most nuclei (P6.papr and P6.ppar), which were not stained at an earlier stage.

[0138] FIG. 20E shows vulval cells containing four nuclei (P5.ppar, P6.paar, P6.pppr and P7.papr) on the right side of the worm.

[0139] FIG. 21A is a Nomarski photomicrograph of a lin-12 gain-of-function (gf) mutant nematode.

[0140] FIG. 21B is a photomicrograph showing anti-SQV-4 antibody staining in a lin-12 gain-of-function mutant nematode with multiple psuedovulva (pv) and one functional vulva (v). The formation of the pseduovulval extracellular space coincides with increased expression of SQV-4 in the pseudovulvae.

[0141] FIG. 22A is a Nomarski photomicrograph of a lin-11 loss-of-function (lf) mutant nematode with a reduced vulval extracellular space.

[0142] FIG. 22B is a photomicrograph showing anti-SQV-4 antibody staining in a lin-11 loss-of-function mutant nematode.

[0143] FIG. 23A is a Nomarski photomicrograph of a wild-type L4 larva with fully-grown vulval extracellular space (v). The vulval and uterine (u) extracellular spaces are separated by a thin planar cytoplasmic process of a uterine cell (utse).

[0144] FIG. 23B is a Nomarski photomicrograph of a sqv-4(n2827) loss-of-function (lf) homozygous L4 larva carrying a transgene array (nEx(sqv-4-gfp)) that expresses a rescuing SQV-4-GFP fusion protein under the control of the native sqv-4 promoter. The vulval extracellular space (v) is larger than in the wild-type nematode.

[0145] FIG. 23C is a Nomarski photomicrograph of a wild-type L4 larva with a nearly undetectable uterine extracellular space. An almost fully-grown vulval extracellular space (v) is separated from the uterine extracellular space by the anchor cell (ac).

[0146] FIG. 23D is a Nomarski photomicrograph of a sqv-4(n2827) heterozygous L4 larva carrying a transgene array (nEx(Phs::sqv-4)) that expresses SQV-4 under the control of the heat-shock promoter. The vulval extracellular space is larger than in the wild-type nematode and is larger at the dorsal end than at the ventral end.

[0147] FIG. 24A shows the genetic and physical maps for sqv-5. A dashed horizontal line depicts the deficiency qDf10 and indicates the possible extent of the left end point of this deletion, which is between cosmids K10C3 and C03C11. Short solid horizontal lines represent cosmid clones that were assayed in germnlie transformation experiments. Cosmid K09A8, which rescued the sqv-5 mutant phenotype, is shown in bold.

[0148] FIG. 24B shows a partial restriction map of K09A8, the cosmid that was used to derive subclones assayed for rescue of the sqv-5 phenotype. The structure of the sqv-5 gene, as deduced from the genomic and cDNA sequences, is shown below the restriction map. Predicted genes in the minimal rescuing fragment are shown with solid boxes indicating exons and an arrow indicating the 3′ poly A sequence. The extent of the sqv-5(n3611) deletion is indicated by a horizontal line.

[0149] FIG. 24C shows sqv-5 rescue data, which is expressed as the number of transformed lines that rescue/total number of lines tested. The minimal rescuing fragment is indicated with a thick black line. The symbol, {circumflex over ( )}A, indicates the introduction of a four base pair addition/frameshift in the T24D1.1 coding sequence. Asterisks (*) indicate the introduction of a nonsense codon (W664opal, Y160amber, G21 opal) in the T24D1.1 coding sequence.

[0150] FIG. 25 is a sequence alignment of SQV-5 (SEQ ID NO: 24) and its human (SEQ ID NO: 25) and Drosophila melanogaster (SEQ ID NO: 26) homologs. The numbers on the right indicate amino acid positions. Amino acids that are identical between at least two proteins are shaded in black. The extent of the sqv-5(n3611) deletion and the sqv-5(n3039) nonsense allele are indicated. The putative transmembrane domains are underlined. The addition of two amino acids (FQ) after the third amino acid in a longer alternatively spliced form of SQV-5 is indicated.

[0151] FIG. 26 shows the genomic sequence of the C. elegans sqv-5 (SEQ ID NO: 27) minimal rescuing fragment.

[0152] FIG. 27 shows the nucleic acid sequence of a C. elegans sqv-5 cDNA (SEQ ID NO: 28) containing 5′ and 3′ untranslated regions (UTR).

[0153] FIG. 28 shows the nucleic acid sequence of a human sqv-5 cDNA (ORF 477-2885) (SEQ ID NO: 29).

[0154] FIG. 29 is a photomicrograph showing that an anti-SQV-5 antibody stained punctuate foci in all vulval cells.

[0155] FIG. 30A shows anti-SQV-1 antibody staining in oocytes.

[0156] FIG. 30B shows anti-SQV-5 antibody staining in oocytes.

[0157] FIG. 30C is a merged image of FIGS. 30A and 30B, showing that SQV-5 and SQV-1 reside in the same subcellular compartment.

[0158] FIG. 31 is a schematic diagram showing a model for the function of the eight sqv genes.

DESCRIPTION OF THE INVENTION

[0159] We have identified and characterized five sqv genes, sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6, that function together in a eukaryotic glycosylation pathway. These genes, or their encoded polypeptides, can be used to identify compounds useful in the treatment of a progeroid syndroms, connective tissue diseases, or glycosylation disorders. We have discovered that sqv-1 encodes a UDP-glucuronic acid decarboxylase; sqv-2 and sqv-6 encode glycosyltransferases; sqv-4 encodes a protein similar to UDP-glucose dehydrogenases; and sqv-5 encodes a chondroitin synthase (CS) that controls the biosynthesis of CS glycosaminoglycans (GAGs), but not of heparan sulfate (HS) GAGs.

[0160] SQV-1 and SQV-4 act in nucleotide-sugar biosynthesis and synthesize UDP-xylose and UDP-glucuronic acid, respectively. Although all developmental defects caused by mutations in these two genes have been observed in all other sqv mutants, we suspect that additional defects could be present in mutants defective in these two genes because both UDP-glucuronic acid and UDP-xylose are used in non-GAG glycosylation.

[0161] SQV-2 is the C. elegans GAG galactosyltransferase II, and SQV-6 is the C. elegans GAG xylosyltransferase; SQV-6, SQV-3, SQV-2, and SQV-8 act in the biosynthesis of the four-sugar linker region (xylose attached to serine-galactose-galactose-glucuronic acid (attached to a repeating disaccharide of glucuronic acid and N-acetylglucosamine or N-acetylgalactosamine) that is necessary for the biosynthesis of chondroitin and heparan sulfate GAGs and that covalently links the GAGs to the protein core of proteoglycans.

[0162] SQV-5 is the C. elegans chondroitin synthase. This finding represents the first characterization of developmental defects caused exclusively by defective CS biosynthesis. sqv-5 mutants share the phenotypes observed in other sqv mutants, including defects in cytokinesis during C. elegans embryogenesis and defects in vulval and uterine morphogenesis during postembryonic development. Because all of the developmental defects described in other sqv mutants, including defects in cytokinesis during C. elegans embryogenesis and defects in vulval morphogenesis during postembryonic development, are found in sqv-5 mutants, we propose that these developmental defects are also caused by defects in CS biosynthesis.

[0163] sqv-1 Cloning

[0164] We used a positional approach to clone sqv-1. sqv-1 had been previously mapped between phenotypic markers unc-24 and dpy-20 on LGIV (Herman et al., Proc. Natl Acad. Sci. USA 96:968-73, 1999). We mapped sqv-1 to an approximately 400 kb region between bnP4 and the left endpoint of eDf18 and eDf19 (FIG. 1A). Thirteen cosmids in this interval were tested for the ability to rescue sqv-1 mutants. We found that a single cosmid, D2096, rescued sqv-1. A 3.6 kb Eco0109I-HindIII fragment of D2096, containing a single predicted gene D2096.4 (The C. elegans Sequencing Consortium, Science 282:2012-8, 1998), was sufficient to rescue sqv-1 mutants (FIG. lB). The nucleic acid sequences of the C. elegans sqv-1 gene and human sqv-1 are shown in FIGS. 1C and 1D.

[0165] We used the 3.6 kb C. elegans minimal rescuing fragment as a probe to screen a C. elegans embryonic cDNA library and isolated seven cDNA clones. One of the cDNAs obtained contained 1771 bases of open reading frame, untranslated sequence, 3′ poly-A sequence, and a 5′ SL1 trans-spliced leader. The SL1 motif is found at the 5′ end of many C. elegans transcripts (Krause et al., Cell 49:753-61, 1987). The longest open reading frame (ORF) in this cDNA was identical to that predicted for D2096.4 and was predicted to encode a protein of 467 amino acids. Using a fragment containing this ORF, we detected a single 2.1 kb transcript on a Northern blot of mixed-stage total RNA from wild-type nematodes. The expression of the sqv-1 ORF under the control of the C. elegans heat shock promoters (Stringham et al., Mol. Biol. Cell 3:221-33, 1992) rescued the vulval defect and maternal-effect lethality of sqv-1 mutants, indicating that the predicted coding sequence encoded a functional SQV-1 protein.

[0166] We identified six molecular lesions in D2096.4 in five of the six sqv-1 alleles. Five alleles, n2820, n2824, n2828, n2848 and ku246, were missense mutations and one allele, n2819, contained two missense mutations (FIG. 2). The molecular lesion in the sixth allele, n2849, has not been identified. A library of mutagenized worms was screened by PCR to obtain a deletion allele, n3790, which removed the entire coding sequence of sqv-1 (FIG. 1B). Animals homozygous for n3790 showed the same vulval and Mel phenotypes observed in the stronger missense mutations.

[0167] SQV-1 Enzymatic Activity

[0168] SQV-1 contains a potential transmembrane domain near the amino terminus, suggesting it may be a type II transmembrane protein. It is weakly similar to UDP-glucose epimerases and TDP-glucose dehydratases. SQV-1 is 14% (67/467 amino acids) identical to an E. coli UDP-glucose epimerase and 17% identical to a thymidine diphosphate (TDP)-glucose dehydratase (78/467 amino acids). UDP-glucose epimerases catalyze the interconversion of UDP-glucose and UDP-galactose, and TDP-glucose dehydratases convert TDP-glucose to TDP-4,6-keto-deoxy-glucose. Biochemical assays on bacterially expressed SQV-1 failed to detect either of these enzymatic activities. Because the C. elegans genome contains a UDP-glucose epimerase homolog, C47B2.6 (47% identity to the E. coli gene) and two TDP-glucose dehydratase homologs, F53B 1.4 and C01F1.3 (35% and 30% identities to the E. coli genes respectively), we reasoned that SQV-1 is not likely to be the C. elegans UDP-glucose epimerase or TDP-glucose dehydratase.

[0169] Further analysis revealed that SQV-1 is more similar to predicted proteins whose function is undefined. We identified and determined the sequence of human cDNA clones from a National Cancer Institute EST project that encode a protein closely related to SQV-1. The most common form of the predicted human protein was 56% (236/420 amino acids) identical to SQV-1, and the Drosophila melanogaster CG7979 gene product was 54% identical (239/441 amino acids) to SQV-1 (FIG. 2).

[0170] Based on SQV-1's sequence similarity to UDP-glucose epimerases and TDP-glucose dehydratases, we hypothesized that sqv-1 encoded an enzyme that modifies a nucleotide sugar. Many of the previously cloned nucleotide-sugar modifying enzymes involved in GAG biosynthesis do not share a high degree of amino acid identity to SQV-1. Therefore, we tested SQV-1 for enzymatic activities for which the corresponding gene had not yet been cloned in any species. One such enzymatic activity was that of UDP-glucuronic acid decarboxylase, which converts UDP-glucuronic acid to UDP-xylose. UDP-xylose is a donor substrate necessary for the initiation of the GAG-protein core linker region (reviewed by Kjellen et al., Annu. Rev. Biochem. 60:443-75, 1991).

[0171] We found that purified myelin basic protein (MBP)-SQV-1 fusion protein, in the presence of AND+ cofactor, generated UDP-xylose from UDP-glucuronic acid. This enzymatic reaction mixture was analyzed using an HPLC coupled to a mass spectrometer. Ion phase reverse polarity HPLC separated the nucleotide sugars and AND+ into three peaks of elution as detected by UV (FIG. 3A). These peaks were determined by mass spectrometry to be the substrate UDP-glucuronic acid, the product UDP-xylose, and the cofactor NAD+. Negative polarity mass spectra identified the masses of the most abundant compounds in the reaction sample as 579 and 535 (FIG. 3B). These masses corresponded to the molecular masses of UDP-glucuronic acid (580) and UDP-xylose (536). The slight difference in molecular mass (579 versus 580 and 535 versus 536) was due to the negative ionization by the mass spectrometer, which removed one hydrogen atom from each compound. The presence of isotopic masses of 536 and 537 corresponded to subpopulations of UDP-xylose containing heavy isotopes such as 13C.

[0172] Even after a long incubation of the reaction mixture (>1 hour) with MBP-SQV-1 protein, a significant amount of UDP-glucuronic acid was left unconverted (FIG. 3B). In other species, the UDP-glucuronic acid decarboxylase reaction is irreversible, but is inhibited by the product, UDP-xylose (John et al., J. Biol. Chem. 252:6707-10, 1977). The presence of non-decarboxylated UDP-glucuronic acid in our reaction mixture was likely caused by the UDP-xylose inhibiting UDP-glucuronic acid decarboxylase.

[0173] SQV-1 Immunocytochemistry

[0174] We generated affinity-purified rabbit polyclonal antibodies raised against SQV-1-GST fusion protein, and rabbit and rat polyclonal antibodies raised against SQV-1-MBP fusion protein. These antibodies were used for immunolocalization experiments and were found to stain punctate foci in the cytoplasm of many cells in wild-type worms (FIGS. 4A-4D). Staining was observed in the vulval and uterine cells (FIGS. 4C and 4D), and stronger staining was observed in oocytes and coelomocytes (FIGS. 4A and 4B), cells in the pseudocoelom that may function as scavengers. This punctate staining was not seen in animals homozygous for the sqv-1(n3790) null allele. The presence of SQV-1 in the vulva of wild-type animals is consistent with SQV-1 having a function in vulval morphogenesis. The presence of SQV-1 in oocytes is also consistent with a cell-autonomous role in embryonic development.

[0175] sqv-1 Rescuing Construct

[0176] A translational fusion of the sqv-1 open reading frame (ORF) and green fluorescent protein (GFP), fused to the sqv-1 carboxy terminus was expressed under the control of the endogenous sqv-1 promoter in sqv-1 mutants. This construct rescued sqv-1 mutants vulval defect and maternal-effect lethality. SQV-1-GFP was expressed in many of the same tissues in which SQV-1 antibody staining had been seen, including the vulva, gut, pharynx, seam cells and coelomocytes.

[0177] SQV-1 Colocalizes With the SQV-7 Nucleotide-Sugar Transporter

[0178] We reasoned that the punctate cytoplasmic staining of anti-SQV-1 antibodies was likely caused by the localization of SQV-1 to a specific subcellular compartment, such as the Golgi bodies. SQV-7, a multipass transmembrane protein capable of transporting nucleotide sugars required for GAG biosynthesis across membranes (Hennan et al., Proc. Natl. Acad. Sci. USA 96:974-9, 1999; Berninsone et al., Proc. Natl. Acad. Sci. USA 98:3738-43, 2001), was also expected to localize to the Golgi. SQV-7 was predicted to translocate UDP-glucuronic acid, UDP-galactose and UDP-N-acetylgalactosamine from the cytosol to the lumen of the Golgi (Berninsone et al., Proc. Natl. Acad. Sci. USA 98:3738-43, 2001). To test whether SQV-1 and SQV-7 colocalized, we raised rabbit polyclonal antisera against a 26 amino acid peptide corresponding to the SQV-7 carboxy-terminus and affinity-purified the antisera against the same SQV-7 peptide.

[0179] We found that anti-SQV-7 antibodies stained punctate foci in the cytoplasm of several tissues in wild-type nematodes, including the vulva, seam cells, distal tip cells, and oocytes (FIGS. 5A-5D). The presence of SQV-7 in the vulva and oocytes is consistent with SQV-7 functioning in both vulval morphogenesis and embryonic development. We obtained a null allele of sqv-7, (n3789), that deleted the entire ORF by PCR screening a deletion library (FIG. 5E). In animals homozygous for the sqv-7(n3789) null allele, SQV-7 antibodies did not stain punctate foci in the vulval, seam and distal tip cells or oocytes.

[0180] A translational fusion, which contained the sqv-7 ORF fused with GFP at the SQV-7 carboxy terminus, was expressed under the control of the endogenous sqv-7 promoter in wild-type nematodes that were assayed by fluorescence microscopy for GFP expression. Punctate GFP fluorescence was observed in seam cells, consistent with the seam cell staining observed with anti-SQV-7 antibodies. In cells that had only a low level of SQV-7-GFP fluorescence, the SQV-7 GFP colocalized with small granular bodies in seam cells, which had been previously identified as Golgi bodies by Singh et al. (Singh et al., Nematologica 24:63-71, 1978). SQV-7's localization to the Golgi membranes is consistent with its proposed function as a nucleotide-sugar transporter.

[0181] Using rat anti-SQV-1 antibodies and rabbit anti-SQV-7, we found that SQV-1 and SQV-7 colocalized in the same or adjacent compartments in oocytes (FIG. 6A-C), in vulval cells, and in the pharynx. Based on our results with SQV-1 and SQV-7 antibodies, we predicted that significant amounts of SQV-1 and SQV-7 protein would be present in the Golgi bodies of several cell types, including oocytes, and present at lower concentrations in most, if not all, other cells.

[0182] Through sequence analysis, we found that homologs of C. elegans SQV-1, in human and Drosophila, have a potential transmembrane domain near the amino terminus, suggesting that the conversion of UDP-glucuronic acid to UDP-xylose is made in the Golgi lumen in many other species. Indeed, Kearns et al. (J. Biol. Chem. 268, 11097-1041993) found that UDP-glucuronic acid decarboxylase activity and xylosyltransferase activities are similarly localized in chondrocytes. In chondrocytes, xylosylation of GAGs is carried out in the vesicular regions of endoplasmic reticulum (ER) and continues in the early Golgi (Vertel et al., J. Biol. Chem. 268:11105-12, 1993). Most glycosyltransferases, including all glycosyltransferases involved in the biosynthesis of GAGs, act in the lumen of the ER and Golgi (reviewed by Varki, Trends Cell Biol. 8:34-40, 1998). Production of UDP-xylose in the lumen of the Golgi may allow for more efficient feedback inhibition of the decarboxylation reaction by restricting the diffusion of UDP-xylose. It seems likely that SQV-1 and SQV-7 act in the late ER as well as in the Golgi. Decarboxylation of UDP-glucuronic acid is the only reaction known to produce UDP-xylose. Interestingly, mammalian UDP-xylose transporter activities for transporting UDP-xylose from the cytosol to the Golgi lumen have been described biochemically using purified Golgi and ER vesicles (Kearns et al., J. Biol. Chem. 268:11097-104, 1993).

[0183] sqv-7 Mutant Progeny Fail to Initiate Cvtokinesis

[0184] Herman et al. (Proc. Natl. Acad. Sci. USA 96:968-73, 1999) reported that most progeny of mutants homozygous for stronger mutant alleles of sqv-1 to -7 arrest as one-cell stage embryos. We examined the embryonic arrest phenotype of sqv mutants by comparing the development of wild-type embryos and the progeny of mutants homozygous for the sqv-7(n3789) null allele.

[0185] In wild-type nematodes, fertilization triggers meiosis in oocytes and extrusion of a polar body, which contains the excess maternal DNA that remains after meiosis. We observed fertilization in wild-type embryos, and found that at about this time the oocyte plasma membrane and eggshell become visible, and the space between the plasma and vitelline membranes expands (FIG. 7A-7C). Shortly before the fusion of the maternal and paternal haploid pronuclei, the embryonic plasma membrane constricted in a process termed pseudocleavage (FIG. 7B). The maternal and paternal pronuclei, which were initially located at opposite ends of the embryo, then migrated to the middle of the embryo where they fused and then rotated around each other (FIGS. 7C and 7D). Aster and mitotic spindle formation and nuclear division then occurred, followed by cytokinesis (FIG. 8A-8C).

[0186] While sqv-7 null mutant oocytes were fertilized normally, we failed to detect polar body extrusion, pseudocleavage, or separation of the plasma membrane and eggshell in most sqv-7 null mutant embryos (FIG. 7D-7F). The timing of migration, fusion, rotation of the sperm and egg pronuclei, and separation of postmitotic nuclei was similar to that observed in wild-type embryos (FIG. 7D-7F). In sqv-7 null mutants, however, nuclear division was not accompanied by the initiation of cytokinesis (FIG. 8D-8F). Following the first nuclear division, the sqv-7 null mutant embryos contained at least three nuclei (FIG. 8F), in contrast to the two nuclei normally observed in wild-type embryos (FIG. 8C). We suspected that the extra nuclei were derived from unextruded polar bodies. DAPI staining confirmed that these extra nuclei contained DNA. These nuclei divided repeatedly in the absence of cytokinesis, resulting in a multinucleate embryo.

[0187] Cellular Express of SQV-1 and SQV-7

[0188] We found that SQV-1 is expressed at a high level in coelomocytes, but SQV-7 is not. Conversely, SQV-7 is expressed at a high level in seam cells, but SQV-1 is not. One possible explanation for these differences in cellular expression is that different levels of SQV proteins result in different compositions of GAGs. For example, if a large amount of nucleotide sugars, used in GAG biosynthesis, is present in a cell, but only a small amount of UDP-xylose is available, because of low expression of SQV-1, such a cell may have a smaller number of GAG molecules, but the length of each GAG molecule may be longer. Conversely, if UDP-xylose levels in a cell are high, but other nucleotide sugar levels are low, such a cell may have a larger number of short GAG molecules. Alternatively, the main function of SQV-1 and SQV-7 in coelomocytes and seam cells may not be the biosynthesis of chondroitin and heparan sulfate GAGs.

[0189] Cloning of sqv-2

[0190] sqv-2 was previously mapped to the left of lin-31 on LGII. We further mapped sqv-2 to an interval between sup-9 and lin-31. Although twenty-seven cosmids in this interval were assayed, none rescued the sqv-2 mutant phenotype (FIG. 9A).

[0191] We examined the DNA sequence corresponding to the gaps between the cosmids in this interval and found a predicted gene, Y110A2AL.14, that is weakly similar to galactosyltransferases. Because other sqv genes function in the biosynthesis of chondroitin and/or heparan sulfate GAGs, we reasoned that sqv-2 might also encode a protein involved in GAG biosynthesis. We sequenced the sqv-2 candidate gene, Y110A2AL.14 (FIG. 9B), in two of the strongest sqv-2 alleles, n3037 and n3038. n3037 and n3038 mutants display a maternal effect lethal (Mel) phenotype. The nucleic acid sequences of C. elegans SQV-2 and the SQV-2 human homolog are shown in FIGS. 9C and 9D, respectively. In the n3037 allele, we identified a nonsense mutation in the codon that codes for amino acid 225 (FIG. 10), and in n3038, we identified a missense mutation at the predicted start codon (FIG. 10). In a weak allele of sqv-2, n2826, which gives live progeny, we identified a missense mutation that encoded a glycine-to-arginine substitution at amino acid position 99. The molecular lesion present in the weakest allele of sqv-2, n2840, has not yet been identified.

[0192] We sequenced two cDNA clones, yk94e4 and yk292g2, that correspond to Y110A2AL.14. The yk292g2 clone contained 990 bases of ORF, 17 bases of 5′ untranslated region (UTR), and 121 bases of 3′ UTR. The 5′ end contained three bases that corresponded to a 5′ SL1 trans-spliced leader, which marks the 5′ end of many C. elegans transcripts (Krause et al., Cell 49:753-61, 1987). The 3′ end contained a poly A sequence. The longest ORF in this cDNA is identical to Y110A2AL.14 and is predicted to encode a protein of 330 amino acids. The yk94e4 clone lacked the 5′ end of Y110A2AL.14. The expression of the longest ORF in yk292g2 under the control of the C. elegans heat-shock promoters (Stringham et al., Mol. Biol Cell 3:221-3, 1992) rescued the sqv-2 mutant phenotype.

[0193] RNA-mediated interference (RNAi), a method of specific gene inactivation (Fire et al., Nature 391:806-11, 1998), was induced by feeding wild-type nematodes E. coli expressing double-stranded Y110A2AL.14 RNA. The progeny of these animals exhibited a variable Mel phenotype very similar to the strongest alleles of sqv-2.

[0194] sqv-2 Encodes a Protein Similar to GAG Galactosyltransferase II

[0195] The predicted SQV-2 protein contains a putative transmembrane domain near the amino terminus, suggesting it may be a type TI transmembrane protein. All glycosyltransferases identified to date are type II transmembrane proteins that act in the lumen of the ER/Golgi. SQV-2 was 29% (95/330 amino acids) identical to a Drosophila homolog and 40% (132/330 amino acids) identical to a human homolog (FIG. 10). Recently, the human homolog of SQV-2 was identified as a GAG galactosyltransferase II by Bai et al. (J. Biol. Chem. 276:48189-95, 2001).

[0196] SQV-2 Has GAG Galactosyltransferase II Activity

[0197] We assayed a recombinant Protein A-SQV-2 fusion protein expressed in COS7 cells for galactosyltransferase II activity. The SQV-2 fusion protein specifically catalyzed addition of galactose to a disaccharide acceptor, galactose-(β1,4)-xylose(β1)-O-benzyl (Galβ1,4Xylβ1-O-Bn), which was used to demonstrate the acceptor substrate specificity of the human GAG galactosyltransferase II (Bai et al., J. Biol. Chem. 276:48189-95, 2001) (Table 1).

TABLE 1
Acceptor substrate specificity of SQV-2 fusion protein.
		Enzyme
		Activity (pmol/
Acceptor Substrates		h/mL medium)
Monosaccharides (5 mM)	Xylβ1-O-Bn	0
	Xylβ31-O-naphthol	0
	Galβ1-0-NM	0
	GalNAcβ1-O-Bn	0
	GlcNAcβ1-O-NM	0
Disaccharides (5 mM)	Galβ1,4Xy1β1-O-Bn	2660
	Galβ1,3GalNAcα1-O-NM	1
	Galβ1,3Galβ1-O-NM	3
	Galβ1,4GlcNAcβ1-O-NM	0
	Galβ1,3GlcNAcβ1-O-NM	0
	GlcNAcβ1,3Galβ1-O-NM	6
	Manα1,6Manα1-O-C10	0
Table Legend: NM, naphthalenemethanol, Bn, benzyl; C10, O-decenyl (CH2)8CH = CH2

[0198] Galactosyltransferase activity was assayed in vitro using UDP-[3H]galactose together with various acceptor substrates. None of the other acceptors tested acted as an acceptor for glycosylation by SQV-2, including the monosaccharide acceptor counterpart, xylose-(β1)-O-benzyl (Xylβ1-O-Bn) and a related acceptor, xylose-(β1)-O-naphthalenemethanol (Xylβ1-O-naphthol). Xylβ1-O-Bn, or a chemically similar acceptor, have previously been used to demonstrate the acceptor substrate specificity of SQV-3 GAG galactosyltransferase I and its human homologs (Almeida et al., J. Biol. Chem. 274:26165-71, 1999; Okajimaetal., J. Biol. Chem. 274:22915-8, 1999b; Buliket al., Proc. Natl. Acad. Sci. USA 97:10838-43, 2000), which are predicted to catalyze a previous glycosylation step to that catalyzed by SQV-2.

[0199] Molecular Identification of sqv-6

[0200] sqv-6 was previously mapped to the left of the stP3 polymorphism of LGV (Herman et al., Proc. Natl. Acad. Sci. USA 96:968-73, 1999). We further mapped sqv-6 to the left of cosmid W07B8, near unc-34. Eleven cosmids to the right of unc-34 were assayed for the ability to rescue the sqv-6 mutant phenotype, but none rescued (FIG. 11A).

[0201] We examined the DNA sequence in the gaps in the cosmid coverage near the cosmid W07B8 and unc-34 and found a gene, Y50D4C.d, that is similar to two recently identified human GAG xylosyltransferases (Gotting et al., J. Mol. Biol. 304:517-28, 2000). We noticed that unc-34 is is located 5′ to Y50D4C.d. By nucleic acid sequencing, we identified a molecular lesion, a nonsense mutation causing a deletion of the last 42 amino acids of the predicted protein product, corresponding to sqv-6 (n2845), in the ORF of Y50D4C.d (FIG. 11B). The nucleic acid sequence of C. elegans SQV-6 is shown in FIG. 11C.

[0202] We sequenced PCR-amplified cDNA and 5′-rapid amplification of cloned ends (RACE) products corresponding to Y50D4C.d. We determined that the cDNA contains a 5′ SL1 trans-spliced leader, 23 bases of 5′ UTR, and 2418 bases of ORF, including two additional 5′ exons not found in Y50D4C.d. The longest ORF in this cDNA, including the additional exons, is predicted to encode a protein of 806 amino acids. The expression of this ORF under the control of the C. elegans heat-shock promoters (Stringham et al., Mol. Biol. Cell 3:221-33, 1992) rescued the sqv-6 mutant phenotype.

[0203] sqv-6 Encodes a Protein Similar to GAG Xylosyltransferases

[0204] The SQV-6 protein is 23% (182/806 amino acids) and 24% (193/806 amino acids) identical to human xylosyltransferases I and II, respectively (FIG. 12A). The predicted SQV-6 protein and human xylosyltransferase II contain a putative transmembrane domain near the amino terminus, and are likely type II transmembrane proteins. No start codon and no presumptive transmembrane domain has been defined in human xylosyltranferase I (Gotting et al., J. Mol. Biol. 304:517-28, 2000).

[0205] sqv-6 Can Correct a Xylosyltransferase Defect in CHO Cells

[0206] We tested the ability of sqv-6 to act as a GAG xylosyltransferase by testing its ability to complement Chinese hamster ovary (CHO) mutant cells defective in this enzymatic activity (FIG. 12B). Wild-type CHO-K1 cells incorporated most exogeneous 35SO4 into GAGs; 55% (+/−5%) and 40% (+/−5%) of incorporated 35SO4 was present in chondroitin sulfate and heparan sulfate, respectively (Esko et al., Proc. Natl. Acad. Sci. USA 82:3197-201, 1985). The mutant CHO pgsA-745 cells, which are defective in the biosynthesis of GAGs, were dramatically reduced in GAG xylosyltransferase activity (Esko et al., Proc. Natl. Acad. Sci. USA 82:3197-201, 1985).

[0207] We transiently transfected mutant pgsA-745 cells with a plasmid encoding SQV-6. We then tested GAG xylosyltransferase activity in the mutant pgsA-745 cells and in the sqv-6 transiently transfected cells. We found that the sqv-6 transiently transfected cells were able to incorporate 35SO4 into macromolecules inside and on the surface of the cells (Table 2).

TABLE 2
Content of sulfated GAGs in CHO cells transformed with sgv-6
		Average 35
	Temp.	incorporation	Percent
Strain	° C.	cpm / μg protein	incorporation
wild-type CHO-K1 trial 1	37	1364	100
mutant pgsA-745 trial 1	37	16	1
pgsA-745 + vector trial 1	37	16	1
pgsA-745 + sqv-6 trial 1	37	354	26
wild-type CHO-K1 trial 2	37	766	100
mutant pgsA-745 + trial 2	37	19	2
pgsA-745 + vector trial 2	37	19	2
pgsA-745 + sqv-6 trial 2	37	207	27
wild-type CHO-K1 trial 3	37	436	100
mutant pgsA-745 trial 3	37	10	2
pgsA-745 + vector trial 3	37	10	2
pgsA-745 + sqv-6 trial 3	37	88	20
wild-type CHO-K1 trial 4	30	890	100
mutant pgsA-745 trial 4	30	15	2
pgsA-745 +vector trial 4	30	20	2
pgsA-745 + sqv-6 trial 4	30	286	32
wild-type CHO-K1 trial 5	30	1014	100
mutant pgsA-745 trial 5	30	23	2
pgsA-745 + vector trial 5	30	23	2
pgsA-745 + sqv-6 trial 5	30	163	16

[0208] The average 35S incorporation into polysaccharides in two wells of CHO cells are shown in Table 2. In five separate trials, 35SO4 incorporation in the sqv-6 transfected cells ranged from 16% to 27%. In contrast, 35SO4 incorporation ranged from 1% to 2% in the untransfected pgsA-745 cells and in cells transfected with the vector alone.

[0209] Molecular Identification of sqv-4

[0210] sqv-4 had been mapped between unc-42 and sma-1 on LGV (Herman et al., Proc. Natl. Acad. Sci. USA 96:968-73, 1999). We then mapped sqv-4 to an. approximately 300 kb region between the left endpoint of sDf35 and emo-1. We then carried out germline transformation rescue experiments. Of the 13 cosmids in this interval tested, two overlapping cosmids, C32C4 and C04G9, rescued sqv-4 (FIG. 13A). Within the overlapping region between C32C4 and C04G9, we identified a 4.8 kb EcoRV-XhoI fragment, containing a single gene, F29F 11.1, that was sufficient to rescue the sqv-4 mutant phenotype (FIG. 13B).

[0211] We used this 4.8 kb minimal rescuing fragment as a probe to screen a C. elegans embryonic cDNA library and isolated six cDNA clones. One of the cDNAs we obtained appeared to be complete; it contained 1443 bases of open reading frame, 142 bases of untranslated sequence, a 3′ poly-A sequence, and a 5′ SLI trans-spliced leader, a sequence found at the 5′ end of many C. elegans transcripts (Krause et al., Cell 49:753-61, 1987). The longest open reading frame within this cDNA is identical to F29F11.1 (FIG. 13C) and is predicted to encode a 481 amino acid polypeptide. Using this cDNA as a probe, we detected a single 1.9 kb transcript in C. elegans mixed-stage total RNA on a northern blot. The nucleic acid sequence of C. elegans sqv-4 is shown in FIG. 13D.

[0212] We expressed this presumptive sqv-4 open reading frame (ORF) under the control of C. elegans heat-shock promoters (Stringham et al., Mol Biol. Cell 3:221-33, 1992) and found that this expression rescued the sqv-4 mutants vulval defect and maternal-effect lethality. This indicated that the predicted coding sequence encodes a functional SQV-4 protein (Table 3).

TABLE 3
sgv-4 mutant phenotype rescue by heat-shock
induced expression of sgv-4.
Heat shock (hours)a	Stageb	% non-Sqvc (n)	% Fertiled (n)
1	embryo	13 (31)	3 (31)
7	embryo	32 (19)	5 (19)
16	embryo	100 (6)	0 (6)
22	embryo/L1	95 (40)	0 (40)
38	L1/L2	100 (24)	0 (24)
45	L1/L2	100 (15)	4 (24)
54	L2/L3	100 (13)	0 (13)
63	L3/L4	33 (15)	100 (15)
88	adult	—	94 (17)
117	adult	—	38 (24)
aThe time of heat shock after the eggs were laid.
bDevelopmental stage (as determined by visual examination using a dissecting microscope) at which heatshock treatment occurred.
c% non-Sqv, percentage of Rol animals that rescued the L4 vulval phenotype.
d% Fertile, number of Rol animals that rescued the Mel phenotype (that had progeny grow to adulthood).
The numbers in parenthesis (n) indicate the total numbers of animals examined.

[0213] sqv-4(n2827)/nT1(n754) adult hermaphrodites carrying an extrachromosomal array of sqv-4 coding sequence fused to the C. elegans heat-shock promoters and a Rol marker were allowed to lay eggs at 20° C. for two hours. SQV-4 expression was then induced by a thiry minute heat-shock treatment at 33° C.

[0214] We found that heat-shock-induced expression of sqv-4 from late embryogenesis through the second larval (L2) stage was sufficient to rescue the sqv-4 vulval defect, but failed to rescue the maternal-effect lethality. To rescue maternal-effect lethality, heat-shock-induced expression of sqv-4 is required in third or fourth stage (L3-L4) larvae or in young adults. These data indicated that sqv-4 acts during at least two distinct phases of C. elegans delopment.

[0215] We identified molecular lesions in F29F11.1 in sqv-4 mutants. Both mutant and n2840, are missense mutations that are predicted to cause an arginine-to-histibstitution at amino acid position 353 and a threonine-to-isoleucine amino acid position 420, respectively (FIG. 14).

[0216] RNA-mediated interference (RNAi) is a method that allows the inactivation of (Fire et al., Nature 391:806-11, 1998). We injected wild-type nematodes with double-stranded sqv-4 RNA, and found that the progeny of these injected animals exhibited a Mel phenotype similar to that of sqv-4 mutants. When wild-type nematodes were fed a strain of E. coli that expresses double-stranded sqv-4 RNA (RNAi by feeding), the progeny of these animals exhibited a variable Sqv and Mel phenotype.

[0217] sqv-4 Encodes a Protein Similar to UDP-Glucose Dehydrogenases

[0218] The predicted SQV-4 protein is similar in amino acid sequence to a family of UDP-glucose dehydrogenases from vertebrates, insects and plants (FIG. 14). UDP-glucose dehydrogenase catalyzes the conversion of UDP-glucose and NAD+ to UDP-glucuronic acid and NADH (Strominger et al., J. Amer. Chem. Soc. 76:6411-6412, 1954; Hempel et al., Protein Science 3:1074-1080, 1994) (FIG. 15A). Two molecules of NAD+ are converted to NADH for each molecule of UDP-glucose that is converted to UDP-glucuronic acid (Strominger et al., J. Amer. Chem. Soc. 76:6411-6412, 1956). Of the 481 amino acids of SQV-4, 304 (63%), 304 (63%) and 271 (56%) amino acids are identical to human, Drosophila melanogaster, and Arabidopsis thaliana UDP-glucose dehydrogenases, respectively (FIG. 14). The two amino acids, R353 and T420, that are altered in the sqv-4 mutant alleles, are conserved among all known metazoan UDP-glucose dehydrogenases.

[0219] SQV-4 Has UDP-Glucose Dehydrogenase Activity

[0220] We expressed recombinant SQV-4 protein in E. coli and tested the bacterially-expressed protein for UDP-glucose dehydrogenase activity (FIG. 15A). Enzymatic activity was measured by monitoring the reduction of NAD+ at 340 nm in the presence of UDP-glucose or other nucleotide sugars. Spectrophotometric measurement indicated that UDP-glucose dehydrogenase activity was increased at least 20-fold in lysates containing wild-type SQV-4 protein compared to lysates from cells transfected with either the vector alone or containing mutant SQV-4 protein. Bacterially-expressed SQV-4 protein that contained a histidine for arginine substitution at amino acid position 353, corresponding to the sqv-4 mutant allele, n2827, resulted in a greater than 20-fold decrease in UDP-glucose dehydrogenase activity (FIG. 15B). Substitution of isoleucine for threonine at amino acid position 420, corresponding to the mutant allele n2840, caused the SQV-4 protein to become insoluble. This insoluble protein could not be tested for enzymatic activity. NAD+ reduction was undetectable if UDP-glucose was replaced with TDP-, ADP-, CDP- or GDP-glucose, or UDP-galactose, -mannose, -glucuronic acid, or —N-acetyl-glucosamine.

[0221] We measured the initial velocities of this reaction varying concentrations of either UDP-glucose or NAD+. A double-reciprocal plot of the initial velocities revealed a Km of 0.2 mM for UDP-glucose (FIG. 16A), and a Km of 0.2 mM for NAD+ (FIG. 16B). These Km values were comparable to those of UDP-glucose dehydrogenases from other species (e.g., chicken UDP-glucose dehydrogenase, which has Kms of 0.5 mM for UDP-glucose and 0.9 mM for NAD+; E. coli, which has Kms of 1 mM for UDP-glucose and 0.05 mM for NAD+; and Streptococcus pyogenes UDP-glucose dehydrogenase, which has Km's of 0.02 mM for UDP-glucose and 0.06 mM for NAD+ (Bdolah et al., Biochim. Biophys. Acta 159:176-178, 1968; Schiller et al., Biochim. Biophys. Acta 293:1-10, 1973; Campbell et al., J. Biol. Chem. 272:3416-3422, 1997)).

[0222] SQV-4 Protein Expression is Dynamically Regulated in Vulval Cells During Vulval Morphogenesis

[0223] We raised rabbit polyclonal antisera against a GST-SQV-4 fusion protein and affinity purified anti-SQV-4 antibodies using a MBP-SQV-4 fusion protein. The anti-SQV-4 antibodies recognized a protein of approximately 53 kDa in worm extracts (FIG. 17) that is the predicted size of the SQV-4 protein.

[0224] SQV-4 antibodies stained the cytoplasm of many cells, including (but not limited to) oocytes (FIG. 18) and vulval cells (FIG. 19A-C) as well as uterine, seam, pharyngeal and spermathecal cells. The cytoplasmic localization of SQV-4 is consistent with the idea that nucleotide sugar biosynthesis is catalyzed in the cytoplasm, and the nucleotide-sugars are then translocated into the endoplasmic reticulum and/or Golgi, where polymerization of sugars is catalyzed by glycosyltransferases for the biosynthesis of GAGs. SQV-4's expression in the developing vulva is consistent with its functioning in a cell-autonomous fashion in vulval morphogenesis. The presence of SQV-4 in oocytes is likely to be necessary for normal embryonic development.

[0225] In wild type nematodes, the vulva consists of the twenty-two descendants of the ventral hypodermal cells, P5.p, P6.p and P7.p. During the L3 larval stage, P5.p and P7.p divide to make seven vulval descendants each, while P6.p divides to make eight vulval descendants (Sulston et al., Dev. Biol. 56:110-56, 1977). During the L4 stage, the twenty-two vulval nuclei migrate inward and dorsally, with the inner nuclei of the P6.p descendants assuming the most dorsal positions and the outer nuclei of the P5.p and P7.p descendants assuming the most ventral positions (Sharma-Kishore et al., Development 126:691-9, 1999). During the L4 stage, the P5.p and the anterior half of the P6.p descendants are separated from the P7.p and the posterior half of the P6.p descendants by the expanding vulval extracellular space. This extracellular space expands so that the separation at the dorsal end is smaller than the separation at the ventral end. Then the middle of the vulval extracellular space widens, resulting in a bottle-like shape. Finally, the dorsal end of the vulval extracellular space expands toward the uterine cavity, and the vulval extracellular space fuses with the uterine cavity. Many of the vulval cells fuse homotypically at various points during vulval morphogenesis, ultimately generating nine cells containing 22 nuclei (Sharma-Kishore et al., Development 126:691-9, 1999). In sqv-4 mutants, the expansion of the vulval invagination space is impaired.

[0226] The twenty-two vulval nuclei define three classes of nuclei based on the levels and timing of their SQV-4 expression. In early L4 larva, ten nuclei are in vulval cells with dramatically increased SQV-4 expression. These 10 nuclei are the six inner nuclei of the P5.p and P7.p descendants, and the four outer nuclei of the P6.p descendants. In late L4 larva, the inner four nuclei of the P6.p descendants show increased SQV-4 expression. Thus, fourteen vulval nuclei are in cells that highly express SQV-4 (FIGS. 20A-20E).

[0227] The increased expression of SQV-4 in L4-stage vulval cells suggested that the nematode requires a high level of UDP-glucuronic acid for normal vulval morphogenesis. Increases in vulval cell UDP-glucuronic acid likely result in increases in the amount and length of chondroitin and heparan sulfate GAGs. The temporal and spatial increase of SQV-4 expression in a subset of the vulval cells corresponds to the stereotypical changes in the shape of the vulval extracellular space during the L4 stage. The widening of the middle of the vulval extracellular space coincides with increased SQV-4 expression in the cells containing 10 vulval nuclei located in the center of the dorso-ventral axis. The final expansion of the dorsal end of the extracellular space coincides with the increased expression of SQV-4 in the cells containing the four dorsal-most vulval nuclei.

[0228] SQV-4, tagged with GFP at its carboxy terminus, was expressed under the control of the endogenous sqv-4 promoter in transgenic sqv-4 mutant animals. We found that this expression was sufficient to rescue the vulval defect and maternal-effect lethality of sqv-4 mutants. We found SQV-4::GFP expression in many tissues that were stained by SQV-4 antibodies, including the vulva, uterus, gut, seam cells, and hypodermis. SQV-4::GFP expression was absent from oocytes; this absence was likely due to germline silencing of the SQV-4::GFP transgenic array (Kelly et al., Genetics 146:227-38, 1997). GFP expression was observed in vulval cells containing 10 nuclei in the early L4 stage, and in vulval cells containing 14 nuclei in the later L4 stage, consistent with the antibody staining.

[0229] SQV-4 Expression in lin-12(gf) Mutants and lin-11 (lf) Mutants

[0230] In wild-type early L3 larvae, ventral hypodermal cells, P5.p, P6.p and P7.p, form a row along the ventral side of the worm. P3.p and P4.p are at the anterior end of this group and P8.p is posterior. P3.p, P4.p and P8.p divide once, each generating two descendants that do not participate in vulva formation. In lin-12 gain-of-function (gf) mutants, cells P3.p to P8.p divide aberrantly, generating seven descendants each. Anti-SQV-4 antibodies stained a subset of cells in pseudovulvae and vulva in lin-12 (g) mutants (FIGS. 21A and 21B). This resulted in the formation of four pseudovulvae and one functional, but abnormal, vulva. Each pseudovulvae contained seven nuclei, while the functional vulva contained fourteen nuclei (Greenwald et al., Cell 34:435-44, 1983). SQV-4 antibodies strongly stained three nuclei of each pseudovulva and six nuclei of the functional vulva of lin-12(gf) mutant L4 stage larvae. This result was consistent with the elevated expression of SQV-4 in three of the seven descendants of P5.p and P7.p observed in wild-type worms.

[0231] In lin-11 loss-of-function (lf) mutants, P5.p and P7.p each generated eight vulval descendants. The lin-11(lf) P5.p and P7.p cell lineages were different from the wild-type P6.p cell lineage, which also generates eight descendants, in the orientation of the final cell division: the final wild-type P6.p divisions are along the left-right axis, while the final lin-11 P5.p and P7.p divisions are along the anterior-posterior axis (Freyd et al., Nature 344:876-9, 1990). lin-11 mutants have an abnormally small vulval extracellular space, which is distinct from that of the sqv mutants, as only the ventral region is reduced in lin-11 mutants. In lin-11 (lf) mutants, SQV-4 antibody staining was weaker and observed in fewer vulval cells relative to wild-type nematodes (FIG. 22A and 22B). This difference in SQV-4 expression likely caused the smaller vulval extracellular space present in lin-11 mutants.

[0232] Nematodes with Multiple Copies of sqv-4 Exhibited Increased Vulval Extracellular Space

[0233] We analyzed vulval extracellular space in rescued sqv-4 mutant animals expressing a transgenic array in which the sqv-4 open reading frame (ORF) was linked to GFP, and expressed under the control of the endogenous sqv-4 promoter. Many of these rescued transgenic animals had vulval extracellular spaces that were increased in size relative to wild-type nematodes (FIG. 23A-23B). When SQV-4 was expressed under the C. elegans heat-shock promoter in sqv-4 mutant animals, we found that some of these transgenic L4 larva also had a larger than wild-type vulval extracellular space. In these animals, however, the shape of the extracellular space was affected. The dorsal width of the vulval extracellular space in these PhsSqv-4 transgenic animals was approximately five times larger than that observed in wild-type animals (FIG. 23C-23D).

[0234] Nematodes carrying a sqv-4 trangenic array are likely to have many copies of the sqv-4 gene and abnormally high levels of SQV-4 protein. Increased SQV-4 levels likely increases the size of the vulval extracellular space. The abnormal shape of the vulval extracellular space observed when the sqv-4 transgene was expressed under the heat-shock promoter may be caused by premature SQV-4 expression in the four inner descendants of the P6.p. Thus, regulation of sqv-4 appears to control the shape of the vulval extracellular space and the surrounding vulval epithelia during vulval morphogenesis. This observation is consistent with the regulation of SQV-4 expression at the transcriptional level.

[0235] Molecular Identification of sqv-5

[0236] We used a positional approach to clone sqv-5. First, by physically mapping deficiency endpoints, we localized sqv-5 to a roughly 200-kilobase region between the left endpoint of qDf10 and fog-3 (FIG. 24A). Of nine cosmids that were injected, K09A8 rescued the sqv-5 mutant phenotype. A 18,448 base BamHI-PstI fragment of K09A8, containing a single complete gene, T24D1.1, was sufficient to rescue sqv-5 mutants (FIG. 24B and C). The minimal rescuing fragment is shown in FIG. 26. Introducing a nonsense or a frameshift mutation in T24D1.1 abrogated the rescuing activity of the 18 kb Bam HI-PstI fragment. We identified the molecular lesion of the first sqv-5 mutant allele, n3039, as a late nonsense mutation in the open reading frame (ORF) of T24D1.1 (FIG. 25). We obtained a new deletion mutant allele of sqv-5, n3611, which showed the same Sqv mutant phenotype as n3039 (FIG. 25). We also found three DNA sequence discrepancies between our DNA sequencing results and results of the C. elegans Sequencing Consortium, which caused us to reevaluate and change the gene structure of T24D1.1 (FIG. 24B).

[0237] We sequenced two cDNA clones, yk20d7 and yk21g9, that roughly correspond to T24D1.1, and also sequenced six 5′-rapid amplification of cloned ends (RACE) products derived from mixed stage RNA. The 5′ RACE products contained a 5′ SL1 trans-spliced leader, which is found at the 5′ end of many C. elegans transcripts. We determined that the sqv-5 cDNA contained 417 bases of 5′ untranslated region (UTR), 2202 bases of open reading frame, and 657 bases of 3′ UTR sequence. Two alternatively spliced forms of the transcript were identified; the shorter form is shown in FIG. 27. The longer form contains six additional bases in the ORF; the polypeptide encoded by this cDNA is shown in FIG. 25. The longest ORF in the sqv-5 cDNA was predicted to encode a protein of 734 or 736 amino acids; both proteins are larger than the protein predicted by T24D1.1. Using a 1827 bp fragment corresponding to the 3′ segment of the ORF, we detected a single 3.6 kb transcript in mixed-stage total RNA on a Northern blot.

[0238] The short form of sqv-5 contains 734 amino acids; 277 of which are identical to a recently cloned human chondroitin synthase (38% identical) (Kitagawa et al., J. Biol. Chem. 276:38721-6, 2001). The sequence of a human sqv-5 homolog cDNA is shown in FIG. 28. We also identified and DNA sequenced a cDNA of a Drosophila melanogaster homolog that is predicted to encode a 832 amino acid protein, which shares 38% amino acid identity with SQV-5 (FIG. 25). Alternatively, 262 of 734 amino acids of SQV-5 are identical to the Drosophila genome project's deduced polypeptide which contains 788 amino acids (FIG. 25). All three proteins contain a single predicted transmembrane domain near the N-terminus, consistent with a type TT transmembrane topology typical of glycosyltransferases localized to the lumen of ER or Golgi.

[0239] sqv-5 Mutants Have Reduced Chondroitin Synthase Activity

[0240] sqv-5(n3611), sqv-5(n3611)/hT2, and wild-type (N2) animals were used to prepare worm protein extracts. These extracts were tested for chondroitin synthase activity using standard methods, for example, in DeAngelis et al., (J. Biol. Chem. 27:24124-24129, 2000).

[0241] Table 4 shows the result of biochemical assays for chondroitin synthase activity in protein extracts from wild-type (+/+), sqv-5 heterozygotes (sqv-5(n3611)/hT2) (+/sqv-5), and sqv-5(n3611) homozygotes (sqv-5/sqv-5). A desulfated chondroitin acceptor was used for the GalNAcT (N-acetylgalactosamyl transferase) assay. Desulfated and β-glucuronidase-treated chondroitin acceptor was used for the GlcAT (glucuronyl transferase) assay.

TABLE 4
sgv-5 protein extracts have reduced chondroitin synthase activity
	Donor Sugar	Genotype	CPM
	UDP-glucuronic acid	+/+	1820
		+/sqv-5	1369
		sqv-5/sqv-5	109
	UDP-N-acetylgalactosamine	+/+	171
		+/sqv-5	134
		sgv-5/spv-5	<0
	+/+ is wild-type; +/sqv-5 is sqv-5(n3611)/hT2; and sqv-5/sqv-S is sqv-5(n3611);

[0242] SQV-5 Expression

[0243] To study the expression and subcellular localization of SQV-5 protein in C. elegans, we generated affinity-purified rabbit polyclonal antibodies against SQV-5-GST fusion protein. Anti-SQV-5 antibodies stained multiple punctate foci in the cytoplasm of vulval cells, (FIG. 29), uterine cells, and oocytes. This punctate staining was not seen in nematodes homozygous for the sqv-5(n3611) null allele.

[0244] A similar punctate staining pattern was observed using antibodies against SQV-7 nucleotide sugar transporter and SQV-1 UDP-glucuronic acid decarboxylase. Anti-SQV-1 rat antibodies and anti-SQV-5 rabbit antibodies were used to determine whether SQV-1 and SQV-5 proteins colocalized to the same cytoplasmic compartment. We found that SQV-1 and SQV-5 staining colocalized to the same or adjacent compartment in oocytes (FIG. 30A-30C).

[0245] SQV-5 Mutants Fail to Initiate Cytokinesis

[0246] sqv-5 mutants failed to initiate cytokinesis. This may have resulted from a failure of the plasma membrane to separate from the eggshell. We also noticed that the uterus in the sqv-5 mutant adult was unusually small. We measured the length of the uterus in young adults in various sqv mutant backgrounds, and found strong uterine defects in sqv-5 and sqv-1 mutant nematodes, and milder uterine defects in sqv-4, -7 and -8 mutant nematodes; the sqv-4 and sqv-8 mutant alleles tested may not represent null mutations. The length of the uterus was restored to wild type length in sqv-1 and sqv-4 mutant nematodes by expression of a sqv-1-gfp and sqv-4-gfp extrachromosomal array, respectively.

[0247] Function of the Eight sqv Genes

[0248] A model for the function of the eight sqv genes is shown in FIG. 31.

[0249] Working Examples

[0250] sqv-1 Strains and Genetics

[0251] C. elegans strains were cultured as described by Brenner (Genetics 77:71-94, 1974)). The wild-type strain used was N2 (Brenner, Genetics 77:71-94, 1974). The mutant strains used were described by Riddle et al. (C. elegans II. Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press, 1997)), except as follows: LGII sqv-7(n3789) is described herein; mnC1 (dpy-10(e128) unc-52(e444)) was described by Herman, (Genetics 88:49-65, 1978); LGIV sqv-1(n2819, n2820, n2824, n2828, n2848, n2849, n3790) are described herein; LGIV sqv-1 (ku246) was obtained from Min Han; unc-24(e138), dpy-20(e1282), fem-3(q20), mes-6(bn66), eDf18, and eDf19 were described by Hodgkin et al., (Cold Spring Harb. Symp. Quant. Biol. 50:585-93, 1985), and nT1(n754) was described by Ferguson et al., (Genetics 110:17-72, 1985). The strain RW7000, which displays multiple RFLPs relative to wild-type Bristol N2, was described by Emmons et al., (Cell 32:55-65, 1983) and Liao et al. (Proc. Natl. Acad. Sci. USA 80:3585-9, 1983).

[0252] sqv-1 had been previously mapped between unc-24 and dpy-20 on LGIV (Herman et al., Proc. Natl. Acad. Sci. USA 96:968-73, 1999). We further mapped sqv-1 to an approximately 400 kb region between the TC1 polymorphism bnP4 and the left endpoint of the deficiencies eDf18 and eDf19 (FIG. 1A). To map sqv-1, Unc non-Sqv progeny were obtained from unc-24(e138) sqv-1(n2819)/fem-3(q20) hermaphrodites. Dpy non-Sqv progeny were obtained from sqv-1(n2819) dpy-(n1282)/fem-3(q20) hermaphrodites. All 11 Unc non-Sqv progeny carried fem-3(q20) and 27 of 34 Dpy non-Sqv progeny carried fem-3(q20). We obtained Unc Dpy non-Sqv progeny from mes-6(bn66) dpy-20(e1282)/unc-24(e138) sqv-1(n2819) hermaphrodites. All 8 Unc Dpy progeny carried mes-6(bn66).

[0253] We obtained Unc non-Sqvs from unc-24(e138) sqv-1(n2819)/++ (RW7000) hermaphrodites and Dpy non-Sqvs from sqv-1(n2819) dpy-20(e1282)/++ (RW7000) hermaphrodites. An initial survey of 26 Dpy non-Sqvs indicated that two of them carried the Tc1 polymorphisms bnP3 and bnP2, but did not carry the Tc1 polymorphism bnP4. One Dpy non-Sqv carried only bnP2. We next determined whether bnP4 was present in additional recombinants. We found that all 35 Unc non-Sqvs carried bnP4 and 72 of 75 Dpy non-Sqvs carried bnP4. These results placed sqv-1 to the left of bnP4. Both dpy-20(e1282) sqv-1(n2819)/eDf18 and dpy-20(e1282) sqv-1(n2819)/eDf19 animals were Sqv.

[0254] We obtained eDf18 and eDf19 dead eggs from unc-24(e138) dpy-20(e1282)/eDf18 or unc-24(e138) dpy-20(e1282)/eDf19 hermaphrodites. We attempted to PCR amplify genomic DNA sequences corresponding to cosmids B0218, C07G1 (overlapping with T09A12), F35H10, and D2096 (see FIG. 1A). Four eDf19 eggs contained the genomic DNA sequence from B0218, but not F35H10 and D2096. This placed the left endpoint of eDf19 between B0218 and F35H10. Three eDf18 eggs contained the genomic DNA sequence from B0218, but did not contain F35H10 and D2096. Eleven eDf18 eggs contained genomic DNA sequence from B0218 and C07G1, but did not contain F35H10. These results placed the left endpoint of eDf18 between C07G1 and F35H10, thus placing sqv-1 to right of C07G1/T09A12.

[0255] Isolation of sqv-1 Deletion Alleles

[0256] Null mutations sqv-1(n3790) and sqv-7(n3789) were isolated from a library of animals mutagenized with UV illumination and trimethylpsoralen essentially as described by Jansen et al (Nat. Genet. 17: 119-21, 1997) and Liu et al. (Genome Res. 9, 859-67, 1999) and backcrossed six times to N2. The deletion in sqv-1(n3790) removed bases 2981 to 5690 of the cosmid D2096 and the entire sqv-1 coding sequence. The deletion in sqv-7(n3789) removed bases 17746 to 19294 of the cosmid C52E12 and all but the first and part of the second exon of sqv-7. sqv-7(n3789) also contained a tandem duplication of bases 19295 to 19316 of the cosmid C52E12.

[0257] Generation of Transgenic Animals

[0258] We injected genomic DNA into unc-24(e138) sqv-1(n2819)/dpy-20(e1282) hermaphrodites at concentrations of 3-7 μg/ml with the dominant roller marker pRF4 (80 μg/ml) as described by Mello et al. (EMBO J. 10: 3959-3970, 1991). Rol lines were established and Unc Rol animals were examined for rescue of the sqv-1 mutant phenotype.

[0259] sqv-1 Human cDNA Clones

[0260] The sequence of all PCR-amplified DNA used for cloning was confirmed to exclude unintended mutations. The human cDNA clones, 1875025, 1871770, 29917, 210962, 21151921, 32371, 208993, 2630577 and 54339, containing the human homolog of sqv-1, were provided to us by the I.M.A.G.E. consortium (Lennon et al., Genomics 33:151-2, 1996). The clones 1875025 and 1871770 have an identical 5′ end. The clone 29917 contained an alternative spliced form of human sqv-1, which is predicted to encode five additional amino acids not found in 1875025 and 1871770.

[0261] C. elegans sqv-1 cDNAs

[0262] To identify sqv-1 cDNAs, a 3.6 kb Eco0109I-HindlII rescuing fragment was used to probe an embryonic stage lambda-gt11 cDNA library (Okkema et al., Development 120:2175-86, 1994) and to isolate cDNA clones. The isolated cDNA clone that contained the longest open reading frame (ORF) identical to D2096.4 is predicted to encode a protein of 467 amino acids. The D2096.4 ORF was PCR-amplified using the cDNA clone as a template and the oligonucleotides 5′-TCTGGTACCATGCTGAGCCCCAGACG-3′ (SEQ ID NO: 30) and 5′-TCTGAGCTCATCGTCGACTCTCAAG-3′ (SEQ ID NO: 31) as primers. The resulting product was digested with KpnI and SacI and cloned into pPD49.78 and pPD49.83 (from A. Fire). We injected sqv-1(n2828)/nT1(n754) hermaphrodites with the full length sqv-1 ORF fused to the heat-shock promoters (Stringham et al., Mol. Biol. Cell 3:221-33, 1992) in the vectors pPD49.78 (90 μg/ml) and pPD49.83 (85 μg/ml) with pRF4 (80 μg/ml) as the coinjection marker. The expression of sqv-1 was then induced in the transgenic animals by a 30 minute heat-shock treatment at 33° C. Worms that expressed the coinjection marker displayed a characteristic “rolling” phenotype, these Rol animals were examined for rescue of the sqv-1 mutant phenotype.

[0263] UDP-Glucuronic Acid Decarboxylase Assay

[0264] Standard molecular biology techniques were used (Sambrook et al., Molecular Cloning: A Laboratory Manual. Plainview, New York, Cold Spring Harbor Laboratory Pess, 1989) to obtain a construct that encoded a SQV-1-maltose-binding protein (MBP) fusion protein. The sqv-1 coding sequence was cloned into the MBP encoding vector, pMAL-c2. The oligonucleotides 5′-TCTGAATTCATGCTGAGCCCCAGACG-3′ (SEQ ID NO: 32) and 5′-TCTGGATCCTCATCGTCGACTCTCAAG-3′ (SEQ ID NO: 33) were used to PCR-amplify the sqv-1 ORF. The resulting PCR product was cut with EcoRI and BamHI, purified using standard methods, and cloned into pMAL-c2. The resulting construct was then transformed into BL21 pLysS bacterial cells.

[0265] MBP-SQV-1 protein expression was induced by incubating the transformed cells with 1 mM IPTG at 20° C. for 15 hours. The E. coli were pelleted via centrifugation, resuspended in 0.1 M phosphate, pH 7, 1 mM glutathione and 2 mM EDTA, and lysed using a French Pressure Cell. The soluble fraction was separated from insoluble inclusion bodies by centrifugation at 12,000 g for 20 minutes. The soluble MBP-SQV-1 fusion protein was purified by binding the soluble fraction to amylose resin and then eluting the bound MBP-SQV-1 fusion protein with 10 mM maltose.

[0266] Approximately 10 μg of purified MBP-SQV-1 was then incubated with 2 mM UDP-glucuronic acid and 2 mM NAD+ for one hour at 22 to 23° C. Nucleotide sugars were separated from protein by twenty minutes of centrifugation through a Microcon YM-10 (Millipore) filter equilibrated with water and methanol. The eluate was diluted 100-fold with water and mixed with an equal volume of methanol, injected into a capillary ion pair reverse phase-HPLC (C 18), and eluted with increasing concentrations of methanol. The HPLC column was coupled to an electrospray time-of-flight mass spectrometer (Mariner Workstation, PerSeptive Biosystems, Inc.) to detect the mass of nucleotide sugars present in the reaction sample.

[0267] Anti-SQV-1 and SQV-7 Antibodies and Immunostaining

[0268] A twenty-six amino acid ((C)RSKSTTISYKPLPMTMPIDVHKPRN) (SEQ ID NO: 34) peptide corresponding to the carboxy-terminal end of SQV-7 was synthesized and injected into two rabbits. The anti-SQV-7 antisera was affinity purified by binding to the SQV-7 peptide conjugated to the SULFOLINK COUPLING GEL (Pierce) affinity column. Antibodies were then eluted with 100 mM glycine, pH 2.5, according to the manufacturer's instructions.

[0269] The full length sqv-1 ORF was cloned into the vectors pGEX-4T3 and pMAL-c2 to generate glutathion stransferase (GSI)-SQV-1 and MBP-SQV-1 fusion proteins, respectively. The oligonucleotides 5′-TCTCCCGGGGCATGCTGAGCCCCAGAC-3′ (SEQ ID NO: 35) and 5′-TCTCTCGAGTCGTCGACTCTCAAGACC-3′ (SEQ ID NO: 36) were used to PCR-amplify the sqv-1 ORF; the resulting PCRproduct was cut with XmaIand XhoI, purified using standard methods, and cloned into pGEX-4T3. Expression of the GST-SQV-1 and MBP-SQV-1 fusion proteins was induced by incubation with 1 mM IPTG at 37° C. for three hours, and both fusion proteins were purified by isolating inclusion bodies, as described above, followed by SDS-PAGE and electroelution of the fusion proteins. GST-SQV-1 was injected into two rabbits (Covance). MBP-SQV-1 was injected into two rabbits and two rats (Covance). The anti-GST-SQV-1 antibodies were affinity purified by incubating the anti-GST-SQV-1 anti-sera with the MBP-SQV-1 fusion protein bound to OPTITRAN (S&S) reinforced nitrocellulose strips and then eluting the bound antibodies with 100 mM glycine, pH 2.5.

[0270] Anti-MBP-SQV-1 antibodies were affinity purified by incubating the anti-MBP-SQV-1 antisera with GST-SQV-1 fusion proteins bound to OPTITRAN reinforced nitrocellulose strips and eluting the purified antibodies with 100 mM glycine, pH 2.5.

[0271] Whole worms were fixed and stained using standard methods.

[0272] Expression of SQV-1-GFP and SQV-7-GFP in Nematodes

[0273] We isolated a 5.4 kb PstIl-SalI fragment that included 3,520 bases of genomic DNA upstream of sqv-1 and all but 3 bases of the sqv-1 ORF. This piece of DNA was cloned into the vector pPD95.81 (from A. Fire), resulting in a sqv-1-GFP translational fusion construct. This construct was then injected into sqv-1(n2828)/nT1(n754) and sqv-1(n2849)/nT1(n754) hermaphrodites at a concentration of 23 μg/ml. Transgenic progeny were used to establish GFP-positive lines that were determined to rescue both sqv-1 alleles.

[0274] We generated a NotI site at the 3′ terminus of the sqv-7 ORF in a 14 kb MluI-PstI fragment containing bases 4250 to 8601, 11205 to 15320, and 16143 to 21512 of the cosmid C52E11. Two rounds of PCR amplification were done using the sqv-7 minimal rescuing MluI-PstI fragment minus the internal (bases 8602 to 11204 of the cosmid C52E11) SphI fragment (Herman et al., Cold Spring Harb. Symp. Quant. Biol. 62:353-9, 1999) as the template. The first round of PCR was used to amplify two overlapping sequences. The first sequence was amplified with 5′-GATCTTGGAAAGTATGG-3′ (SEQ ID NO: 37) and 5′-TTGAACATTTGCGGCCGCGTTCCTTGGCTTGTG-3′ (SEQ ID NO: 38), the mutagenic primer, to introduce a NotI site to the 3′ end of sqv-7 ORF. The second sequence was amplified using primers 5′-TACTACAACCTGCGTTG-3′ (SEQ ID NO: 39) and 5′-GTTCGCTTTTTAGTCCCG-3′ (SEQ ID NO: 40) to amplify an overlapping sequence. In the second round of PCR amplification, primers 5′-GATCTTGGAAAGTATGG-3′ (SEQ ID NO: 41) and 5′-GTTCGCTTTTTAGTCCCG-3′ (SEQ ID NO: 42) were used and two products from the first round of PCR acted as the templates. The resulting product was digested with Clal and BsmI and cloned into a pBluescript II vector (Stratagene) containing a SalI-PstI fragment (bases 16041 to 21512 of C52E11) of cosmid C52E11. The resulting construct was digested with BamHI (using the BamHI site at the base 16143 of C52E11 and a second site in the multicloning site (MCS) of pBluescript II) and cloned into a second pBluescript II vector that contained the sqv-7 minimal rescuing MluI-PstI minus SphI fragment that was digested with BamHI (thus removing bases 15320 to 16143 of C52E11) and the NotI site of MCS blunted and self ligated. We then cloned a 1011 base pair NotI fragment that codes for GFP from pPD102.33 (from A. Fire) into the new NotI site of the final construct. We injected either DNA construct (40-50 μg/ml) into sqv-7(n2844) unc-4(e120)/mnC1 (dpy-10(e128) unc-52(e444)) hermaphrodites with the dominant roller marker pRF4 (50 μg/ml). Although this GFP construct failed to rescue the sqv-7 mutant phenotype, an equivalent DNA construct that contained an HA tag (instead of GFP) rescued the sqv-7 mutant phenotype (Berninsone et al., Proc. Nat. Acad. Sci. USA 98:3738-43, 2001).

[0275] sqv-2 and sqv-6 Strains and Genetics

[0276] Nematode strains were cultured as described by Brenner, (Genetics 77:71-94, 1974) and were grown at 20° to 22° C. except where indicated. The mutations used were described in Riddle et al. (C. elegans II. Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press, 1997), except as follows: ccDf11 and ccDf11 were described by Chen et al. (Science 256:240-3, 1992); lin-8(n3646) was obtained from J. Doll; sDf28, sD32, sDf34, sDf38, sDf39, sDf50, sDf53 were described by Rosenbluth et al.(Genetics 124:615-25, 1990) and nT1(n754) was described by Ferguson et al., (Genetics 110:17-72, 1985). CB4856 (Koch et al., Genome Res. 10:1690-6, 2000), which displays multiple single nucleotide polymorphisms (SNPs), relative to N2, was also used.

[0277] sqv-2 Mapping

[0278] We examined the vulval phenotypes of six sqv-2(n2826)/ccDf1 and nine sqv-2(n2826)/ccDf11 hermaphrodites. We found that sqv-2(n2826)/ccDf1 hermaphrodites had wild-type vulval phenotypes. The sqv-2(n2826)/ccDf11 hermaphrodites displayed a squashed vulval phenotype (Sqv). Thirteen of 73 Variable Abnormal morphology (Vab) progeny from vab-1(e2027)/sqv-2(n2826) hermaphrodites carried sqv-2(n2826), thus placing sqv-2 8.9 map units away from vab-1. Three of 99 Lin-8 progeny from lin-8(n3646)/sqv-2(n2826);nIs130 animals carried sqv-2(n2826), thus placing sqv-2 1.6 map units away from lin-8. Sqv and Sup-9 animals were obtained from sup-9(n1913)/sqv-2(n2826) lin-31(n301) unc-85(e1414);unc-93(e1500) hermaphrodites. Four of 167 Sqv animals gave Sup-9 progeny, thus placing sqv-2 1.2 map units away from sup-9. Five of 222 Sup-9 animals gave Sqv Lin-31 progeny, thus placing sqv-2 to the right of sup-9 and 1.1 map units away from sup-9 (FIG. 9A).

[0279] sqv-6 Mapping

[0280] We examined the vulval phenotype of the genotype sqv-6(n2845)/Df unc-46(e177) wherein Df is either sDf28, sDf32, sDf34, sDf38, sDf39, sDf50 or sDf53. Based on previous mapping of these deficiencies by the C. elegans research community reviewed by Rosenbluth et al., (Genetics 124:615-25, 1990), we tentatively placed sqv-6 to the left of unc-60. We found that only sDf32, sDf34 and sDf53 failed to complement sqv-6(n2845). We obtained Dpy non-Unc and Unc non-Dpy progeny from unc-60(e677) dpy-11(e224)/sqv-6(n2845) hermaphrodites. All 26 Dpy non-Unc progeny carried sqv-6(n2845), and none of 27 Unc non-Dpy progeny carried sqv-6(n2845). This result is consistent with sqv-6 being located to the left of unc-60. One of 99 Unc progeny from unc-60(e677)/sqv-6(n2845) hermaphrodites carried sqv-6(n2845), thus placing sqv-6 0.5 map units away from unc-60. None of 265 Unc progeny from unc-34(s138)/sqv-6(n2845) carried sqv-6(n2845), suggesting sqv-6 is closely linked to unc-34. We obtained 21 Unc non-Sqv progeny from sqv-6(n2845) unc-60(e677)/CB4856. We PCR-amplified genomic DNA sequences in the region between unc-34 and unc-60, using animals wild-type for the sqv-6 locus as a template. We determined the presence of single-nucleotide polymorphisms using N2 and CB4856 as controls. CB4856-specific polymorphism was located in cosmid T21H3 in 15 of 21 recombinants, in the cosmid W07B8 in 17 of 21 recombinants, and in the gap between K10C19 and W07B8 in all 21 recombinants. These results placed sqv-6 to the left of W07B8 (FIG. 11A).

[0281] sqv-2 and sqv-6 Genomic Rescue

[0282] Genomic rescue of sqv-2 and sqv-6 mutant nematodes was assayed by injecting genomic DNA into sqv-2(n2821) and sqv-6(n2845) unc-60(e677)/unc-34(s138) nematodes at concentrations of 3-4 μg/ml. The dominant marker pRF4 (58 μg/ml) was co-injected as described in Mello et al. (EMBO J. 0:3959-3970, 1991) for germline rescue. Nematodes expressing the coinjection marker display a distinctive “roller” phenotype. The presence of Rol lines was established. Rol animals were examined for rescue of the sqv-2 mutant phenotype. Unc-60 Rol animals were examined for rescue of the sqv-6 mutant phenotype.

[0283] sqv-2 cDNA

[0284] Plasmids containing sqv-2 cDNA were excised from phage clones yk94e4 and yk292g2. The plasmid, derived from the yk292g2 clone, contained the full sqv-2 ORF. sqv-2 cDNA was also PCR-amplified using an embryonic stage pACT2 cDNA library (from Z. Zhou) as the template and oligonucleotides corresponding to the ORF of sqv-2 and a pACT2 primer. DNA sequence at the 5′ end of the resulting product corresponding to the sqv-2 locus was identical to the 5′ end of yk292g2.

[0285] The sqv-6 cDNA was PCR-amplified using the embryonic stage pACT2 cDNA library as the template and oligonucleotides corresponding to the ORF of sqv-6 as primers. DNA sequence of the resulting overlapping amplified cDNA fragments was determined, and a set of fragments was cloned into pBluescript II (Stratagene). To determine and clone the 5′ end of sqv-6, we used 5′-rapid amplification of cloned ends (RACE).

[0286] cDNA Rescue of sqv-2

[0287] The sqv-2 ORF was PCR-amplified using the yk292g2 clone as a template and the oligonucleotides 5′-TCTGAATTCAATGAGATTCTACCGAAC-3′ (SEQ ID NO: 43) and 5′-TCTCTCGAGTTATGGAATATTCGATCC-3′ (SEQ ID NO: 44) as primers. The resulting product was digested with EcoRI and XhoI and cloned into a pENTR2B vector (Invitrogen). The sqv-6 ORF in pcDNA3.1 (see below) was digested with Asp7181 and NotI and cloned into the pENTR3C vector. The GATEWAY LR cloning system, which is a site-specific recombination system (Invitrogen) of bacteriophage lambda, was then used to transfer the sqv-2 and sqv-6 ORF into pMB6 and pMB 12 (from M. Boxem and S. Heuvel).

[0288] We injected sqv-2(n2821) hermaphrodites with the sqv-2 ORF tagged with an N-terminal Myc tag and fused to the C. elegans heat-shock promoters (Stringham et al., Mol. Biol. Cell 3:221-33, 1992) in the vectors pMB6 (34 μg/ml) and pMB12 (52 μg/ml) with pRF4 (58 μg/ml) as the coinjection marker. We injected sqv-6(n2845)/nT1(n754) hermaphrodites with the sqv-6 ORF tagged with an N-terminal Myc tag in the vectors pMB6 (37 μg/ml) and pMB12 (58 μg/ml) with pRF4 (58 μg/ml) as the coinjection marker. Rol lines were established, and Rol (non-Unc) animals were examined for rescue of the sqv-2 and sqv-6 mutant phenotype following induction of sqv-2 and sqv-6 expression by thirty minutes of heat-shock treatment at 33° C.

[0289] Galactosyltransferase II Assay

[0290] A sqv-2 coding sequence encoding amino acids 25 to 330 of SQV-2, thus lacking the transmembrane domain at the amino terminus, was cloned into pDEST-CMV-protA vector as follows. The oligonucleotides 5′-TCTGAATTCAATTGTGGATGGGATG-3′ (SEQ ID NO: 45) and 5′-TCTCTCGAGTTATGGAATATTCGATCC-3′ (SEQ ID NO: 46) were used as the primers for PCR-amplification, and the resulting product was digested with EcoRI and XhoI and cloned into pENTR3C. The Gateway LR cloning reaction (Invitrogen) was used to transfer the sqv-2 ORF lacking TM into the Gateway destination vector pDEST-CMV-protA to generate a modified amino-terminal protein A fusion protein using the CMV promoter. The plasmid pDEST-CMV-protA was constructed by cloning the Gateway C.1 reading frame cassette, from the manufacturer, into pRK5F10ProteinA (Wei et al., Proc. Natl. Acad. Sci. USA 90:3885-8, 1993), which was digested with EcoRI and blunted using dNTPs, Klenow fragment and T4 DNA polymerase. This plasmid was designed to express a secreted protein A-SQV-2 (amino acids 25-330) fusion protein in mammalian cells.

[0291] COS7 cells were transiently transfected with pDEST-CMV-protA-sqv-2 using LIPOFECTAMINE (3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA) (Chemical Abstracts Registry name: N-[2-(2,5-bis[(3-aminopropyl)amino]-1-oxpentyl}amino)ethyl]-N,N-dimethyl-2,3-bis(9-octadecenyloxy)-1-propanaminium trifluoroacetate), and the neutral lipid dioleoyl phosphatidylethanolamine (DOPE) in membrane filtered water) (Life Technologies) in accordance with the manufacturer's instructions. The transfected cells expressed a secreted protein A-SQV-2 (amino acids 25-330) fusion protein. After seventy-two hours of incubation, the fusion protein was recovered and purified from the cell culture supernatant by affinity chromatography using IgG-agarose (Wei et al., Proc. Natl. Acad. Sci. USA 90:3885-8, 1993).

[0292] Galactosyltransferase II activity was assayed using UDP-[1-3H]Gal (NEN Life Sciences Products, 12.8 Ci/mmol) and various mono- and di-saccharide acceptor substrates, including Xylβ-O-benzyl (Bn), Xylβ-O-naphthol, Galβ-O-naphthalenemethanol (NM), GalNAcβ-O-NM, GlcNAcβ-O-NM, Galβ,14Xylβ-O-Bn, Galβ1,3GlcNAc α-O-NM, Galβ1,3Galβ-O-NM, Galβ1,4GlcNAcβ-O-NM, Galβ1,3GlcNAcβ-O-NM, GlcNAcβ1,3Galβ-O-NM, Manaα,1,6Man α-O-decenyl (Lugemwa et al., J. Biol. Chem. 271:19159-65, 1996; Sarkar et al., Carbohydr Res 329:221-33, 2000; Brown et al., Bioorg. Med. Chem. 9:815-24, 2001). The standard reaction (25 μl) contained 5 μl of IgG slurry containing the fusion protein, 50 mM 2-(N-Morpholino) ethanesulfonic acid (MES), pH 6.0, 0.3 μCi of UDP-[1-3H]galactose, 150 μM UDP-galactose, 5 mM acceptor, 15 mM MnCl2, 50 mM KCl and 1% TX-100. After incubation at room temperature for 3 hours, the reaction products were diluted with 1 mL of 0.5 M NaCl and applied to a Sep-Pak C18 (100 mg; Waters). After washing with 5 ml of 0.5 M NaCl and water, the radiolabeled products were eluted with 50% methanol, dried and counted by liquid scintillation.

[0293] sqv-6 Rescue of Xylosyltranferase Defect in CHO Cells

[0294] The sqv-6 coding sequence was cloned into pcDNA3.1 and transformed into Chinese hamster ovary (CHO) cells. The oligonucleotides 5′-TCTGGTACCACCATGGTATTCAACGGGACGAC-3′(SEQ ID NO: 47) and 5′-TTCCTCGTCGGAAATCG-3′ (SEQ ID NO: 48) were used for PCR-amplification of the 5′ half of sqv-6, and the oligonucleotides 5′-CGATTTTGAGAGACTTATC-3′ (SEQ ID NO: 49) and 5′-TCTGCGGCCGCTAAATCAAGGTCTGCG-3′ (SEQ ID NO: 50) were used for PCR-amplification of the 3′ half of sqv-6. The resulting products were digested with Asp718I and BamHI, for the 5′ half of sqv-6, and BamHI and NotI, for the 3′ half of sqv-6, and cloned into pcDNA3.1.

[0295] Six-well tissue culture dishes were seeded with 1×105 CHO-Kl or CHO pgsA-745 cells (ATCC) in 2 ml of Ham's F12 growth medium (Ham, Proc. Natl. Acad. Sci. USA 53:288-293, 1965) with 10% fetal bovine serum (FBS), 100 μg/ml streptomycin, and 100 U/ml penicillin G. CHO pgsA-745 cells are defective in the GAG xylosyltranserferase activity (Esko et al., Proc. Natl. Acad. Sci. USA 82:3197-201, 1985). The following day, duplicate wells of pgsA-745 cells were left untreated, transfected with an empty pcDNA3.1 vector, or transfected with the pcDNA3.1-sqv-6 construct. After two days of incubation at 37° C. or 30° C., the medium was removed and replaced with 1 ml of Ham's F12 containing 10% dialyzed (to remove sulfate) FBS, 100 U/ml penicillin G, and 50 μCi/ml 35SO4 (sulfuric acid form, NEN). After one to two hours of incubation, the labeling medium was removed and cell monolayers were washed with phosphate buffered saline. The cells were solubilized with 0.1 N NaOH and an aliquot was assayed for protein content by the method of Bradford. The remaining material was diluted with phosphate buffered saline (PBS) and neutralized with acetic acid, then digested with 2 mg/ml Pronase overnight at 4° C. in the presence of 2 mg carrier chondroitin sulfate A (Sigma). Samples were diluted three-fold with water and run over a 0.5 ml DEAE-Sephacel (Pharmacia) column pre-equilibrated with 0.25 M NaCl, 20 mM NaOAc pH 6.0. After washing with the same buffer, radiolabeled GAGs were eluted with 2.5 ml 1 M NaCl, 20 mM NaOAc, pH 6.0. GAGs were precipitated overnight at 4° C. with four volumes of ethanol. The pellet was resuspended in water and counted by liquid scintillation.

[0296] sqv-4 Molecular Biology

[0297] Standard molecular biological techniques were used (Sambrook et al., Molecular Cloning: A Laboratory Manual. Plainview, N.Y., Cold Spring Harbor Laboratory Pess, 1989). The sequences of all amplified DNA were determined to ensure the absence of unintended mutations.

[0298] sqv-4 Strains and Genetics

[0299] C. elegans was cultured at 20° to 22° C. as described by Brenner (Genetics 77:71-94, 1974). N2 was the standard wild-type strain (Brenner, Genetics 77:71-94, 1974). Mutations used are described by Riddle et al. (C. elegans II. Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press, 1997) with the following exceptions. The following mutations were used: LGI, lin-11(n389); LGIII lin-12(n137), dpy-18(e364); LGV unc-60(e677), dpy-11(e224), odr-2(n2145), mec-1(e1066), unc-42(e270), sDf35 (McKim et al., Genetics 118:49-59, 1988), sqv-4(n2827, n2840), emo-1(oz1), sma-1 (e30) and nT1(n754) (Ferguson et al., Genetics 110:17-72, 1985). The wild-type strain RW7000, which contains many more Tc1 transposable elements than N2, was also used (Emmons et al., Cell 32:55-65, 1983; Liao et al., Proc. Natl. Acad. Sci. USA 80:3585-9, 1983).

[0300] We obtained Unc non-Sqv progeny from unc-42(e270) sqv-4(n2827)/++(RW7000) hermaphrodites and Sma non-Sqv progeny from sqv-4(n2827) sma-1(e30)/++(RW7000) hermaphrodites. All 12 Unc non-Sqv progeny carried the Tc1 polymorphism bP1 (Williams et al., Genetics 131:609-24, 1992), and 12 of 18 Sma non-Sqv progeny carried bP1. We obtained Unc non-Sqv progeny from unc-42(e270) sqv-4(n2827)1emo-1(oz1) and Sma non-Sqv progeny from sqv-4(n2827) sma-1(e30)/emo-1(oz1). All 15 Unc non-Sqv progeny carried emo-1(oz1), and 28 of 36 Sma non-Sqv progeny carried emo-1(oz1). We examined the vulval phenotype of six dpy-18(e364); unc-60(e677) dpy-11(e224) sDf35/sqv-4(n2827) hermaphrodites, and all were non-Sqv. We obtained unc-60(e677) dpy-11(e224) sDf35 dead eggs from dpy-11(e224) odr-2(n2145) mec-1(e1066) unc-42(e270) sqv-4(n2827)/unc-60(e677) dpy-11(e224) sDf35 hermaphrodites or unc-42(e270) sqv-4(n2827)/unc-60(e677) dpy-11(e224) sDf35 hermaphrodites. Using single sDf35 eggs, we amplified genomic DNA sequence corresponding to the cosmids C35A5, T21C9 and/or C32C4 (see FIG. 13a). Cosmid F58E6, which contains unc-42 and is deleted in sDf35, was used as the negative amplification control, and C26B2 and D2096 from LGIV were used as positive controls. PCR products of expected length were amplified for C32C4 (n=3) and T21 C9 (n=5), but not for C35A5 (n=12), which placed the right endpoint of sDf35 between T21C9 and C35A5.

[0301] sqv-4 Rescue

[0302] We injected genomic DNA into unc-42(e270) sqv-4(n2827)/emo-1(oz1) animals at concentrations of 3-7 μg/ml with the dominant roller marker pRF4 (80 μg/ml) as described by Mello et al. (EMBO J. 10, 3959-3970,1991) for germline rescue. Rol lines were established, and Unc Rol animals were examined for rescue of the sqv-4 mutant phenotype.

[0303] sqv-4 cDNA

[0304] To identify sqv-4 cDNAs, a 4.8 kb EcoRV-XhoI rescuing fragment was used to probe an embryonic stage lambda-gt11 cDNA library (Okkema et al., Development 120:2175-86, 1994) and isolate cDNA clones. The cDNA clone that contained the longest ORF identical to F29F11.1 was predicted to encode a protein of 481 amino acids. The F29F11.1 ORF was PCR-amplified using the cDNA clone as a template and the oligonucleotides 5′-TCTGGTACCATGACTGATCAAGTCTTC-3′ (SEQ ID NO: 51) and 5′-TCTGATATCTTAATAACCAGCTGTTCC-3′ (SEQ ID NO: 52) as primers. The resulting product was digested with KpnI and EcoRV and cloned into pPD49.78 and pPD49.83 (from A. Fire). We injected sqv-4(n2827)/nT1(n754) animals with the sqv-4 coding sequence transcriptionally fused to the C. elegans heat-shock promoters (Stringham et al., Mol. Biol. Cell 3:221-33, 1992) in the vectors pPD49.78 (90 μg/ml) and pPD49.83 (85 μg/ml) with pRF4 (80 μg/ml), and Rol lines were established. Rol non-Unc animals were examined for rescue of the sqv-4 mutant phenotype following induction of sqv-4 expression by 30 minutes of heat-shock treatment at 33° C.

[0305] sqv-4 RNAi

[0306] For RNAi by injection, the sqv-4 cDNA was PCR-amplified using lambda-gt11 primers and the cDNA clone as a template. The resulting product was cloned into pBluescript II SK+ (Stratagene), digested with EcoRV and treated with dNTPs and Taq polymerase. RNA was synthesized using T3 and T7 polymerases and injected as described by Fire et al. (Nature 391:806-11, 1998). For RNAi by feeding, the sqv-4 ORF, cloned into a pMAL-c2 expression vector (New England Biological), was digested with XhaI and SalI and cloned into the pPD129.36 feeding vector (Timmons et al., Nature 395:854, 1998). Expression of dsRNA was induced as described by Kamath et al. (Genome Biol. 2:1-102000).

[0307] UDP-Glucose Dehydrogenase Assay

[0308] The sqv-4 coding sequences corresponding to the wild-type, n2827, and n2840 alleles were cloned into the pET21d E. coli expression vector and transformed into BL21 pLysS. The oligonucleotides 5′-GACACACACGAATCATCAGC-3′ (SEQ ID NO: 53) and 5′-GTACTTATCGAGTGGGATG-3′ (SEQ ID NO: 54) were used to generate R353H n2827 and T4101 n2840 mutations, respectively, by site-directed mutagenesis. The oligonucleotides 5′-TCTCCATGGCTGATCAAGTCTTCGG-3′ (SEQ ID NO: 55) and 5′-TCTCTCGAGTTAATAACCAGCTGTTCC-3′ (SEQ ID NO: 56) were used for PCR-amplification of the sqv-4 ORF, and the resulting product was digested with NcoI and XhoI and cloned into pET21d. All three proteins have a threonine to alanine mutation in the second amino acid because of the addition of an NcoI site at the 5′ end. SQV-4 expression was induced by incubation with 1 mM IPTG for three to four hours at 37° C. E. coli were pelleted and resuspended in 50 mM Tris-HCl pH 7.5, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, 2 μg/ml pepstatin A, and aprotinin and lysed using a French pressure cell. The soluble fraction was separated from the insoluble inclusion bodies by centrifugation at 12,000 g for 20 minutes. Most of the recombinant SQV-4 protein was present in the soluble fraction, which was used for the UDP-glucose dehydrogenase assay without further purification.

[0309] UDP-glucose dehydrogenase activity was assayed spectrophotometrically by measuring the reduction of NAD+ in the presence of UDP-glucose at 340 nm (Strominger et al., J. Amer. Chem. Soc. 224:79-90, 1954). All assays were performed at room temperature (20 to 22° C.) in 50 mM Tris-HCl, 2 mM dithiothrietol (DTT), pH 8.7. The initial velocity of the reaction was determined from time points during the first 60 seconds after addition of the SQV-4 extract. The substrate specificity of SQV-4 was examined by measuring NAD+ reduction in the presence of 100 μM NAD+ and 250 μM UDP-galactose, UDP-mannose, UDP-glucuronic acid, UDP-N-acetyl-glucosamine, TDP-glucose, ADP-glucose, CDP-glucose, or GDP-glucose.

[0310] Anti-SQV-4 Antibodies and Immunostaining

[0311] The full-length sqv-4 coding sequence was cloned into vectors pGEX-4T3 and pMAL-c2 to generate GST-SQV-4 and MBP-SQV-4 fusion proteins, respectively. The oligonucleotides used for PCR-amplifications were 5′-TCTCCCGGGTAATGACTGATCAAGTCTTC-3′ (SEQ ID NO: 57) and 5′-TCTCTCGAGATAACCAGCTGTTCCGAATAG-3′ (SEQ ID NO :58), for pGEX-4T3, and 5′-TCTTCTAGAATGACTGATCAAGTCTTC-3′ (SEQ ID NO: 59) and 5′-TCTGTCGACTTAATAACCAGCTGTTCC-3′ (SEQ ID NO: 60), for pMAL-c2. The amplified product was digested with XmaI and XhoI for cloning into pGEX4-3, and with XbaI and Sall, for cloning into pMAL-c2. The GST-SQV-4 and MBP-SQV-4 fusion proteins were purified by isolating the insoluble fusion proteins in inclusion bodies followed by SDS-PAGE and electroelution. GST-SQV-4 was injected into two rabbits (Covance, Princeton, N.J.). Anti-SQV-4 antisera were affinity purified by binding to MBP-SQV-4 fusion protein bound to OPTITRAN reinforced nitrocellulose (Schleicher & Schuell, Keene, N.H.) strips, and eluted with 100 mM glycine, pH 2.5. For western blots, SQV-4 was visualized using horseradish peroxidase conjugated secondary antibodies (Bio-Rad, Hercules, Calif.) and chemiluminescent detection reagents (Pierce, Rockford, Ill.).

[0312] Whole worms were fixed using 40:40:1 parts of Boumn's fixative (15:5:1 parts of saturated picric acid: 37% formnaldehyde:glacial acetic acid):methanol:β3-mercaptoethanol as described by Nonet et al. (J. Neurosci 17:8061-73, 1997). Briefly, the worms were incubated in fixative for thirty minutes at room temperature, frozen with liquid nitrogen, quickly thawed, and incubated at room temperature for an additional ten or thirty minutes. The worms were washed with a solution of BTB 1×Borate buffer, 0.5% Triton X-100, 2% β-mercaptoethanol) several times, until most of the yellow tinge was removed from the worms. The worms were incubated with fresh BTB for two to three hours with a change of BTB after the first hour. The worms were washed with BT (BTB minus the 6-mercaptoethanol) once, and with PBST-A (1×PBS, 1% BSA, 0.5% Triton X-100, 5 mM sodium azide, 1 mM EDTA) once. The worms were blocked with PBST-A for 30 minutes and stored at 4° C. The fixed worms were incubated with anti-SQV-4 antibodies and goat anti-rabbit FITC-conjugated secondary antibodies (Jackson) as described by Finney and Ruvkun (1990).

[0313] The staining patterns observed by whole-mount immunohistochemistry using antibodies from both rabbits were indistinguishable. Pre-immune antisera showed staining comparable to that seen with the secondary antibodies only, and pre-absorption of the antibody using GST-SQV-4 fusion protein reduced the whole-mount staining to background level indicating that the SQV-4 staining was specific. ps Expression of SQV-4-GFP Under a sqv-4 Promoter

[0314] The oligonucleotides 5′-TCTCCCGGGATAACCAGCTGTTCCGAATAG-3′ (SEQ ID NO: 61) and 5′-CCAATATACGAGGTGAGC-3′ (SEQ ID NO: 62) were used to amplify a genomic fragment of sqv-4. The resulting 1.5 kb fragment was digested with XmaI (at the 3′ of sqv-4) and PstIl (in the middle of the sqv-4 locus) and ligated with a PstI-SalI fragment containing genomic DNA spanning the middle of the sqv-4 locus to 6253 bases upstream of the predicted ATG of sqv-4 and a SalI-XmaI fragment of the GFP vector pPD95.79 (from A. Fire). We injected sqv-4(n2827)/nT1(n754) animals with the sqv-4 genomic locus and 6253 bases upstream of the predicted ATG transcriptionally fused to GFP in the vector pPD95.79 (80 μg/ml). GFP-positive lines were established and were found to rescue sqv-4.

[0315] sqv-5 Mapping

[0316] We obtained Unc non-Vul and Vul non-Unc progeny from unc-29(e1072) lin-11(n566)lsqv-5(n3039) hermaphrodites. Five often Unc non-Vul progeny carried sqv-5(n3039), and three of ten Vul non-Unc progeny carried sqv-5(n3039), suggesting sqv-5(n3039) was located to the left of lin-11(n566). We examined the vulval phenotype of animals with the genotype ces-1(n703) Df/sqv-5(n3039) where the Df used was qDf5, qDf7, qDf8, qDf9 and qDf10. All were Sqv except for ces-1(n703) qDf5/sqv-5(n3039). Because qDf5, qDf7, qDf8, qDf9 and qDf10 were previously shown to deletefog-3, but only qDf5 and qDf7 was shown to delete lin-11 (10), this mapping placed sqv-5 to the left of fog-3. Using single qDf10 eggs, we amplified genomic DNA sequence corresponding to cosmids K10C3 and C03C11. PCR product of expected length was amplified for K10C3, but not for C03C11 (n=10), which placed the left end point of qDf10 between K10C3 and C03C11.

[0317] Site-Directed Mutagenesis of Genomic sqv-5 Locus

[0318] To generate genomic sqv-5 fragments with nonsense mutations in T24D1.1, two rounds of PCR were done for each mutation using the 18448 base pair BamHI-PstI rescuing fragment of K09A8 as the template. Two primer pairs were used to amplify overlapping products in the first cycle, and a second round of PCR was done using the two ‘outer’ primers of the first cycle and the two amplified products from the first round as the template. The primers are listed as the ‘outer’ 5′ primer, ‘inner’ 3′ primer, ‘inner’ 5′ primer and ‘outer’ 3′ primer: (1) the outer primer 5′-AAAGTTCCAACACGAGGAG-3′ (SEQ ID NO: 63) (f0a), 5′-GTGTATCAACGTATTTTGCAGC-3′ (SEQ ID NO: 64) (r8), the mutagenic primer 5′-CCTACTCTGAATCCTGTTTGG-3′ (SEQ ID NO: 65) (m167), 5′-CAACACGCATGTATCCATATTG-3′ (SEQ ID NO: 66)(r5) to generate G21 opal mutation; (2) 5′-AAAGTTCCAACACGAGGAG-3′ (SEQ ID NO: 67) (F0a), 5′-ATCGGTAGATCCAAGAGC-3′ (SEQ ID NO: 68) (r7), the mutagenic primer 5′-GATGAATAGGATTGGTTCTTG-3′ (SEQ ID NO: 69) (m528), 5′-CAACACGCATGTATCCATATTG-3′ (SEQ ID NO: 70) (r5) to generate Y160amber mutation; (3) 5′-CGTCCACCAAACAGAACAAC-3′ (SEQ ID NO: 71) (f7a), 5′-GATGTGAACAAGTCCAGG-3′ (SEQ ID NO: 72) (r1), the mutagenic primer 5′-GAAGGATGAGGAAAGGAAGATG-3′ (SEQ ID NO: 73) (mn3039), 5′-AGCATGGGACAATTACTCG-3′ (SEQ ID NO: 74) (r0a) to generate W664opal sqv-5(n3039). The amplified product containing G21 opal or Y160 amber mutation was digested with AatII and StuI, and the amplified product containing W664opal sqv-5(n3039) was digested with Pacl and MluI. The resulting digested product was cloned into pBluescriptll (Stratagene) containing the 18448 base BamHI-PstI rescuing fragment of K09A8, and digested with the same pair of restriction enzymes. To generate a genomic sqv-5 fragment with a four base insertion and frameshift mutation in T24D1.1, a pBluescriptll containing the 18448 base BamHI-PstI rescuing fragment was digested witl MluI and blunted with dNTP, Klenow fragment, and T4 DNA polymerase, and then self ligated.

[0319] Deletion Allele

[0320] Null mutation sqv-5(n3611) was isolated from a library of animals mutagenized with UV illumination and trimethylpsoralen (Jansen et al., Nat Genet 17:119-21, 1997) using an outer primer pair, KOF1 5′-CACTATCCAGTGCAAACG-3′ (SEQ ID NO: 75) and KOR3 5′-CAGCTCTTCCTCTTAATGG-3′ (SEQ ID NO: 76), and a nested primer pair, KOF2 5′-GGTAATCGAGAAGACACG-3′ (SEQ ID NO: 77) and KOR2 5′-GATCGGAACACTCCTTC-3′ (SEQ ID NO: 78). The mutant animals containing sqv-5(n3611) were backcrossed six times. The sqv-5(n3611) deletion removed bases 6124 to 7767 of cosmid T24D1, or 1641 bases. A two base discrepancy results from a DNA sequencing error by the C. elegans Sequencing Consortium. Sqv-5(n3611) is predicted to encode a truncated SQV-5 that is missing 385 amino acids (amino acids 130 to 447) from the middle of SQV-5, and also contains an alanine-to-phenylalanine substitution at amino acid 129.

[0321] Site-Directed Mutagenesis of sqv-5 cDNA

[0322] A pBluescript VECTOR (Stratagene) containing the sqv-5 cDNA corresponding to yk21 g9 was popped out of the LAMBDA-ZAP II (Stratagene) phage according to the manufacturer is directions, and transformed into CJ236 E. coli. Single-stranded plasmid was isolated using R408 helper phage. Site-directed mutagenesis was performned to generate restriction sites at the ends of the sqv-5 coding sequence. The primers used were 5′-AGAAGACACGGGATCCAGTATGCGAGTGCGG-3′ (SEQ ID NO: 79) to generate a 5′ BamHI site, 5′-GATAGCCTTGTCGACTTTCCACCTCTATC-3′ (SEQ ID NO: 80) to generate a 3′ SalI site and 5′-CACATGATAGCGGCCGCGGTTTTCCACCTC-3′ (SEQ ID NO: 81) to generate a 3′ NotI site.

[0323] Anti-SQV-5 Antibody Generation

[0324] A sqv-5 expression vector was generated as follows: sqv-5 coding sequence was cloned into an expression vector by a three-way ligation. The constructs with the newly introduced 5′ and 3′ restriction sites were digested with BamHI, SalI, or NotI, as appropriate, and MluI, which cuts a site located in the middle of the sqv-5 coding sequence.

[0325] The full-length sqv-5 coding sequence was then cloned into expression vectors pGEX-4T3 and pMAL-c2, which were used to generate GST-SQV-5 and MBP-SQV-5 fusion proteins. The GST-SQV-5 and MBP-SQV-5 fusion proteins were then purified by isolating insoluble proteins in inclusion bodies, SDS-PAGE, and electroelution. The GST-SQV-5 fusion protein was injected into two rabbits (Covance). Anti-SQV-5 antisera were affinity purified by incubating the antisera with MBP-SQV-5 fusion protein bound to Optitran (Schleicher & Schuell) strips and eluting the purified antisera with 100 mM glycine, pH 2.5. Whole-mount staining of worms was done according to methods previously described herein.

[0326] Generating Worms For Biochemical Assays

[0327] sqv-5(n3611), sqv-5(n3611)/hT2, and wild-type N2 hermaphrodites were picked as L4 larvae by visual examination using a dissecting microscope. The staged worms were allowed to grow for 23 to 27 hours at 22° ° C., re-examined, then transferred to 1.7-ml plastic tubes containing sterile water. The worms were washed once with water, twice with 50 mM Tris, pH 7.5, and then frozen in 50 μl volumes using liquid nitrogen and maintained at −70° C. Worm protein extracts were obtained by sonication.

[0328] Biochemistry

[0329] The enzymatic activity of SQV-5 was assayed as follows. SQV-5(n3611), sqv-5(n3611)/hT2, and wild-type N2 hermaphrodites were picked as L4 larvae by visual examination of the vulva using a dissecting microscope. The worms staged were allowed to grow for an additional twenty-three to twenty-seven hours at 22° C., re-examined, then transferred to 1.7-ml plastic tubes containing sterile water. The staged worms were washed once with water and twice with 50 mM Tris, pH 7.5, then frozen in a 50 μl volume using liquid nitrogen, and stored at −70° C.

[0330] Worm extracts were assayed for GIcAT glucoronosyltransferase activity by combining 1.3×105 cpm UDP-3H-glucuronic acid donor (NEN), 6 μg β-glucuronidase-treated chondroitin acceptor, and 2.7 μg worm extract in a 25 μl reaction volume containing 0.05% Triton X-100, 10 mM MnCl2, and 100 μM ATP, pH 6.5. GalNAcT activity was detected by combining 1.3 to 3×105 cpm UDP-3H-GalNAc donor (NEN), 12 μg chondroitin acceptor, and 6.7 μg worm extract in a 25 μl reaction volume containing 0.05% Triton X-100 and 10 mM MnCl2, pH 6.5. Reactions were incubated for 3 hours at 25° C., after which time 1 mg carrier chondroitin sulfate A and 500 μl GIcAT or GalNAcT loading buffer were added (GlCAT loading buffer: 20 mM NaOAc, pH 6.0, 2 mg/ml BSA, 10 mM UDP, and 10 mM GlCA; GalNAcT loading buffer: 20 mM NaOAc, pH 6.0, 2 mg/ml BSA, and 10 mM uridine). Samples were loaded onto 0.2 ml DEAE-Sephacel columns equilibrated with 0.1 M NaCl and 20 mM NaOAc, pH 6. Radiolabeled chondroitin was eluted with 1 M NaCl and 20 mM NaOAc, pH 6 and precipitated overnight with 4 volumes of ethanol at 4° C. Pelleted material was resuspended in water and counted by liquid scintillation.

[0331] The chondroitin acceptor used was prepared as follows. Chondroitin sulfate C (Sigma, St. Louis, Mo.) was passed over a DOWEX 50 WX8 ion exchange resin column (H+ form, 200-400 mesh) (Bio-Rad, Hercules, Calif.), neutralized with pyridine, and lyophilized. The sample was desulfated with 90% dimethyl sulfoxide, partially deacetylated with lp% hydrazine sulfate in 70% anhydrous hydrazine, cleaved by high pH nitrous treatment, and reduced by sodium borohydride. Some of the CS preparation was digested with β-glucuronidase (Sigma) to generate GalNAc residues at the reducing end of the oligosaccharide. Uronic acid concentration of both preparations was determined by the Carbazole method (Bitter, et al., Anal. Biochem. 4:330-334, 1962).

[0332] Polypeptide Expression

[0333] In general, polypeptides of the invention may be produced by transformation of a suitable host cell with all or part of a polypeptide-encoding nucleic acid molecule or fragment thereof in a suitable expression vehicle.

[0334] Those skilled in the field of molecular biology will understand that any of a wide variety of expression systems may be used to provide the recombinant protein. The precise host cell used is not critical to the invention. A polypeptide of the invention may be produced in a prokaryotic host (e.g., E. coli) or in a eukaryotic host (e.g., Saccharomyces cerevisiae, insect cells, e.g., Sf21 cells, or mammalian cells, e.g., NIH 3T3, HeLa, or preferably COS cells). Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Rockland, Md.; also, see, e.g., Ausubel et al., supra). The method of transformation or transfection and the choice of expression vehicle will depend on the host system selected. Transformation and transfection methods are described, e.g., in Ausubel et al. (supra); expression vehicles may be chosen from those provided, e.g., in Cloning Vectors: A Laboratory Manual (P. H. Pouwels et al., 1985, Supp. 1987).

[0335] A variety of expression systems exist for the production of the polypeptides of the invention. Expression vectors useful for producing such polypeptides include, without limitation, chromosomal, episomal, and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof.

[0336] One particular bacterial expression system for polypeptide production is the E. coli pET expression system (Novagen, Inc., Madison, Wis.). According to this expression system, DNA encoding a polypeptide is inserted into a pET vector in an orientation designed to allow expression. Since the gene encoding such a polypeptide is under the control of the T7 regulatory signals, expression of the polypeptide is achieved by inducing the expression of T7 RNA polymerase in the host cell. This is typically achieved using host strains that express T7 RNA polymerase in response to IPTG induction. Once produced, recombinant polypeptide is then isolated according to standard methods known in the art, for example, those described herein.

[0337] Another bacterial expression system for polypeptide production is the pGEX expression system (Pharmacia, Peapack, N.J.). This system employs a GST gene fusion system that is designed for high-level expression of genes or gene fragments as fusion proteins with rapid purification and recovery of functional gene products. The protein of interest is fused to the carboxyl terminus of the glutathione S-transferase protein from Schistosoma japonicum and is readily purified from bacterial lysates by affinity chromatography using Glutathione Sepharose 4B. Fusion proteins can be recovered under mild conditions by elution with glutathione. Cleavage of the glutathione S-transferase domain from the fusion protein is facilitated by the presence of recognition sites for site-specific proteases upstream of this domain. For example, proteins expressed in pGEX-2T plasmids may be cleaved with thrombin; those expressed in pGEX-3X may be cleaved with factor Xa.

[0338] Once the recombinant polypeptide of the invention is expressed, it is isolated, e.g., using affinity chromatography. In one example, an antibody (e.g., produced as described herein) raised against a polypeptide of the invention may be attached to a column and used to isolate the recombinant polypeptide. Lysis and fractionation of polypeptide-harboring cells prior to affinity chromatography may be performed by standard methods (see, e.g., Ausubel et al., supra).

[0339] Once isolated, the recombinant protein can, if desired, be further purified, e.g., by high performance liquid chromatography (see, e.g., Fisher, Laboratory Techniques In Biochemistry and Molecular Biology, eds., Work and Burdon, Elsevier, 1980).

[0340] Polypeptides of the invention, particularly short peptide fragments, can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984 The Pierce Chemical Co., Rockford, Ill.).

[0341] These general techniques of polypeptide expression and purification can also be used to produce and isolate useful peptide fragments or analogs (described herein).

[0342] Antibodies

[0343] To generate antibodies, a coding sequence for a polypeptide of the invention may be expressed as a C-terminal fusion with glutathione S-transferase (GST) (Smith et al., Gene 67:31-40, 1988). The fusion protein is purified on glutathione-Sepharose beads, cluted with glutathione, cleaved with thrombin (at the engineered cleavage site), and purified to the degree necessary for immunization of rabbits. Primary immunizations, for example, are carried out with Freund's complete adjuvant and subsequent immunizations with Freund's incomplete adjuvant. Antibody titers are monitored by Western blot and immunoprecipitation analyses using the thrombin-cleaved protein fragment of the GST fusion protein. Immune sera are affinity purified using CNBr-Sepharose-coupled protein. Antiserum specificity is determined using a panel of unrelated GST proteins.

[0344] As an alternate or adjunct immunogen to GST fusion proteins, peptides corresponding to relatively unique immunogenic regions of a polypeptide of the invention may be generated and coupled to keyhole limpet hemocyanin (KLH) through an introduced C-terminal lysine. Antiserum to each of these peptides is similarly affinity purified on peptides conjugated to BSA, and specificity tested in ELISA and Western blots using peptide conjugates, and by Western blot and immunoprecipitation using the polypeptide expressed as a GST fusion protein.

[0345] Alternatively, monoclonal antibodies which specifically bind any one of the polypeptides of the invention are prepared according to standard hybridoma technology (see, e.g., Kohler et al., Nature 256:495-497, 1975; Kohler et al., Eur. J Immunol. 6:511-519, 1976; Kohler et al., Eur. J Immunol. 6:292-295, 1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981; Ausubel et al., supra). Once produced, monoclonal antibodies are also tested for specific recognition by Western blot or immunoprecipitation analysis (by the methods described in Ausubel et al., supra). Antibodies that specifically recognize the polypeptide of the invention are considered to be useful in the invention; such antibodies may be used, e.g., in an immunoassay. Alternatively monoclonal antibodies may be prepared using the polypeptide of the invention described above and a phage display library (Vaughan et al., Nature Biotech 14:309-314, 1996).

[0346] Preferably, antibodies of the invention are produced using fragments of the polypeptide of the invention that lie outside generally conserved regions and appear likely to be antigenic, by criteria such as high frequency of charged residues. In one specific example, such fragments are generated by standard techniques of PCR and cloned into the pGEX expression vector (Ausubel et al., supra). Fusion proteins are expressed in E. coli and purified using a glutathione agarose affinity matrix as described in Ausubel et al. (supra). To attempt to minimize the potential problems of low affinity or specificity of antisera, two or three such fusions are generated for each protein, and each fusion is injected into at least two rabbits. Antisera are raised by injections in a series, preferably including at least three booster injections.

[0347] Screening Assays

[0348] A number of novel nucleic acids and polypeptides are described above that function in a eukaryotic glycosaminoglycan (GAG) biosynthetic pathway; a pathway important in human medicine. As a result these novel compounds and related materials (e.g., antibodies and nucleic acids for RNA interference) may therefore be used to screen for compounds that modulate a eukaryotic GAG biosynthetic pathway. Any number of methods are available for carrying out such screening assays. According to one approach, candidate compounds are added at varying concentrations to the culture medium of cells expressing one of the nucleic acid sequences of the invention. Gene expression is then measured, for example, by standard Northern blot analysis (Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience, New York, 2000), using any appropriate fragment prepared from the nucleic acid molecule as a hybridization probe. The level of gene expression in the presence of the candidate compound is compared to the level measured in a control culture medium lacking the candidate molecule. A compound that modulates the expression of a sqv gene is considered useful in the invention; such a molecule may be used, for example, as a therapeutic to treat a connective tissue disease or disorder related to a defect in GAG biosynthesis, or to treat the normal effects of aging on connective tissues.

[0349] If desired, the effect of candidate compounds may, in the alternative, be measured at the level of polypeptide production using the same general approach and standard immunological techniques, such as Western blotting or immunoprecipitation with an antibody specific for a SQV polypeptide. For example, immunoassays may be used to detect or monitor the expression of at least one of the polypeptides of the invention.

[0350] Polyclonal or monoclonal antibodies (produced as described above) that are capable of binding to such a polypeptide may be used in any standard immunoassay format (e.g., ELISA, Western blot, or RIA assay) to measure the level of the SQV polypeptide. A compound that increases the expression of a SQV polypeptide is considered particularly useful. Again, such a molecule may be used, for example, as a therapeutic to treat a connective tissue disease or disorder.

[0351] Alternatively, or in addition, candidate compounds may be identified that specifically bind to a SQV polypeptide of the invention. The efficacy of such a candidate compound is dependent upon its ability to interact with the SQV polypeptide. Such an interaction can be readily assayed using any number of standard binding techniques and functional assays (e.g., those described in Ausubel et al., supra). For example, a candidate compound may be tested in vitro for interaction and binding with a polypeptide of the invention and its ability to modulate a GAG biosynthetic pathway may be assayed by any standard assays (e.g., those described herein).

[0352] Potential antagonists include organic molecules, peptides, peptide mimetics, polypeptides, nucleic acid ligands, and antibodies that bind to a nucleic acid sequence or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also include small molecules that bind to and occupy the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Other potential antagonists include antisense molecules.

[0353] In one particular example, a candidate compound that binds to a SQV polypeptide may be identified using a chromatography-based technique. For example, a recombinant polypeptide of the invention may be purified by standard techniques from cells engineered to express the polypeptide (e.g., those described above) and may be immobilized on a column. A solution of candidate compounds is then passed through the column, and a compound specific for the SQV polypeptide is identified on the basis of its ability to bind to the SQV polypeptide and be immobilized on the column. To isolate the compound, the column is washed to remove non-specifically bound molecules, and the compound of interest is then released from the column and collected. Compounds isolated by this method (or any other appropriate method) may, if desired, be further purified (e.g., by high performance liquid chromatography). In addition, these candidate compounds may be tested for their ability to render a pathogen less virulent (e.g., as described herein). Compounds isolated by this approach may also be used, for example, as therapeutics to treat or prevent the onset of a connective tissue disease or disorder. Compounds that are identified as binding to SQV polypeptides with an affinity constant less than or equal to 10 mM are considered particularly useful in the invention.

[0354] Each of the DNA sequences provided herein may also be used in the discovery and development of compounds. The encoded protein, upon expression, can be used as a target for the screening of drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

[0355] In one embodiment, a candidate compound that inhibits a eukaryotic GAG biosynthetic pathway is identified by growing wild-type nematodes in the presence of a candidate compound and assaying the effect of the compound on vulval development. Vulval development is compared between nematodes contacted with the candidate compound and control nematodes not contacted with the candidate compound. A candidate compounds that causes a sqv phenotype in at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or even 100% of contacted nematodes is a candidate compound that inhibits a eukaryotic GAG biosynthetic pathway.

[0356] In another embodiment, a candidate compound that enhances a eukaryotic GAG biosynthetic pathway is identified by growing Sqv mutant nematodes in the presence of a candidate compound, and assessing the effect of the compound on vulval development. A candidate compound that suppresses the Sqv phenotype in at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or even 100% of contacted nematodes is identified as a candidate compound that enhances a GAG biosynthetic pathway.

[0357] Test Compounds

[0358] Compounds that may be tested for the ability to modulate the expression of sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 can be from natural as well as synthetic sources. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the methods of the invention. Examples of such extracts or compounds include, but are not limited to, plant-based, fungal-based, prokaryotic-based, or animal-based extracts, fermentation broths, and synthetic compounds, as well as modifications of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, N.H.) and Aldrich Chemical (Milwaukee, Wis.). For example, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, Fla.), and PharmaMar, U.S.A. (Cambridge, Mass.). Natural and synthetically produced libraries may be produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. If desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

[0359] A test compound that modulates the expression of sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6, or its encoded protein, may be used to treat a connective tissue diseases, progeroid disorders, or cellular damage caused by aging.

Treatment

[0360] The invention provides methods for treating connective tissue diseases, progeroid disorders, or the connective tissue damage caused by aging. These treatments may be administered by any of a variety of routes known to those skilled in the art, such as, for example, intraperitoneal, subcutaneous, parenteral, intravenous, intramuscular, or subdermal injection. However, sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 nucleic acids or their encoded proteins may also be administered as an aerosol, as well as orally, nasally, or topically. Standard concentrations used to administer a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 nucleic acid or encoded protein include, for example, 102, 103, 104, 105, or 106 plaque forming units (pfu)/animal, in a pharmacologically acceptable carrier. Appropriate carriers or diluents, as well as what is essential for the preparation of a pharmaceutical composition are described, e.g., in Remington's Pharmaceutical Sciences (18th edition), ed. A. Gennaro, 1990, Mack Publishing Company, Easton, Pa., a standard reference book in this field.

[0361] Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline. For inhalation, formulations may contain excipients, for example, lactose. Aqueous solutions may be used for administration in the form of nasal drops, or as a gel for topical administration. The exact dosage used will depend on the severity of the condition, or the general health of the patient and the route of administration. sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 nucleic acids or their encoded proteins may be administered once, or it may be repeatedly administered as part of a regular treatment regimen over a period of time.

[0362] In addition, the invention provides methods for treating connective tissue disease. A sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 nucleic acid sequence may be introduced into a cell, for example, by using liposome-based transfection techniques, to treat the connective tissue disease, progeroid disorder, or cellular damage caused by aging (Units 9.1-9.4, Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 2001). Such DNA constructs may also be introduced into mammalian cells using an adenovirus, or retroviral or vaccinia viral vectors (Units 9.10 and 16.15-16.19, Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 2001). These standard methods of introducing DNA into cells are applicable to a variety of cell-types.

[0363] Recombinant adenoviral vectors offer several significant advantages for gene transfer therapies. The adenoviruses can be prepared at extremely high titer, infect non-replicating cells, and confer high-efficiency and high-level transduction of target cells in vivo after directed injection or perfusion. Either directed injection or perfusion are appropriate for delivery of vectors containing a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene in a clinical setting.

[0364] In animal models, adenoviral gene transfer has generally been found to mediate high-level expression for at least one week. The duration of transgene expression may be prolonged, and ectopic expression relatively reduced, by using tissue-specific promoters in combination with the sqv gene of choice. Other improvements in the molecular engineering of the adenoviral vector itself have produced more sustained transgene expression and with less inflammation. This is seen with so-called “second generation” vectors harboring specific mutations in additional early adenoviral genes and “gutless” vectors in which virtually all the viral genes are deleted utilizing a Cre-Lox strategy (Engelhardt, et al., Proc. Natl. Acad. Sci. USA 91:6196-6200, 1994; Kochanek, et al., Proc. Natl. Acad. Sci. USA 93:5731-5736, 1996).

[0365] In addition, recombinant adeno-associated viruses (rAAV), derived from non-pathogenic parvoviruses, may be used to express a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene as these vectors evoke almost no cellular immune response, and produce transgene expression lasting months in most systems. Incorporation of a tissue-specific promoter is, again, beneficial. Furthermore, besides adenovirus vectors and rAAVs, other vectors and techniques are known in the art, for example, those described by Wattanapitayakul and Bauer (Biomed. Pharmacother. 54:487-504, 2000), and citations therein.

[0366] A vector carrying a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene can be delivered to the target organ through in vivo perfusion by injecting the vector into the target organ, or into blood vessels supplying this organ (e.g., for the liver, the portal vein (Tada, et al., Liver Transpl. Surg. 4:78-88, 1998)).

[0367] Diagnosis

[0368] The methods of the present invention can be used to diagnose connective tissue diseases or progeroid disorders in a patient, or a predisposition to acquiring such disorders, by determining whether the cells of the patient are defective in the expression of a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6. nucleic acid molecules or polypeptides.

[0369] A genetic lesion in a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 may be identified in a biological sample obtained from a patient using a variety of methods available to those skilled in the art. Generally, these techniques icnlude PCR amplification of nucleic acid from the patient sample, followed by identification of the genetic lesion by either altered hybridization, aberrant electrophoretic gel migration, restriction fragment, length polymorphism (RFLP) analysis, binding or cleavage mediated by mismatch binding proteins, or direct nucleic acid sequencing, such as identification of single nucleic acid polymorphisms (SNPs).

[0370] Any of these techniques may be used to facilitate detection of a genetic. lesion in a candidate gene, and each is well known in the art; examples of particular techniques are described, without limitation, in Orita et al. (Proc. Natl. Acad. Sci. USA 86:2766-2770, 1989) and Sheffield et al. (Proc. Natl. Acad. Sci. USA 86:232-236, 1989). Furthermore, expression of the sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 in a biological sample (e.g., a biopsy) may be monitored by standard Northern blot analysis or may be aided by PCR (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 2001; PCR Technology: Principles and Applications for DNA Amplification, H. A. Ehrlich, Ed., Stockton Press, NY; Yap et al., Nucl. Acids. Res. 19:4294, 1991).

[0371] Once a genetic lesion is identified using the methods of the invention (as is described above), the genetic lesion is analyzed for association with an increased risk of developing a connective tissue disease or progeroid disorder.

[0372] Antibodies against a protein produced by the gene which has the genetic lesion, for example, a SQV-1, SQV-2, SQV-4, SQV-5 or Sqv-6 protein, may be used to detect altered expression levels of the protein. Such altered expression may include a lack of expression, or a change in its mobility on a gel, which in turn indicates a change in the protein structure or size. In addition, antibodies may be used for detecting an alteration in the expression pattern or the sub-cellular localization of the protein. Such antibodies include those that recognize both the wild-type and mutant protein, as well as those antibodies that are specific for either the wild-type or an altered form of the protein. If desired, monoclonal antibodies may also be prepared using the SQV-1, SQV-2, SQV-4, SQV-5 or SQV-6 protein described above using standard hybridoma technology (see, e.g., Kohler et al., Nature 256:495, 1975; Kohler et al., Eur. J. Immunol. 6:511, 1976; Kohler et al., Eur. J. Immunol. 6:292, 1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, New York, N.Y., 1981; Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 2001). Once produced, monoclonal antibodies are also tested for specific SQV-1, SQV-2, SQV-4, SQV-5 or Sqv-6 protein recognition by Western blot or immunoprecipitation analysis (by the methods described in, for example, Ausubel et al. (Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1995).

[0373] Antibodies used in the methods of the invention may be produced using amino acid sequences that do not reside within highly conserved regions, and that appear likely to be antigenic, as analyzed by criteria such as those provided by the Peptide Structure Program (Genetics Computer Group Sequence Analysis Package, Program Manual for the GCG Package, Version 7, 1991) using the algorithm of Jameson and Wolf (CABIOS 4:181, 1988). These fragments can be generated by standard techniques, e.g., by the PCR, and cloned into the pGEX expression vector (Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1995). GST fusion proteins are expressed in E. coli and purified using a glutathione agarose affinity matrix as described in Ausubel et al. (Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1995).

[0374] RNA Interference

[0375] RNA interference (RNAi) is a form of post-transcriptional gene silencing initiated by the introduction of double-stranded RNA (dsRNA). Elbashir et al. reported that 21-nucleotide RNA duplexes introduced into cultured mammalian cells could elicit gene-specific silencing (Nature 411:494-498, 2001). Based on these results, one would predict that a double stranded RNA corresponding to one of the sqv genes (e.g., sqv-1, sqv-2, sqv-4, sqv-5, or sqv-6) described herein could be used to specifically silence sqv gene expression. To this end, the antisense nucleic acids described herein are contemplated to be employed as double-stranded RNA molecules. One in the art will recognize that the other strand of the RNA molecule has the reverse complement sequence of the depicted antisense sequence.

[0376] Use of Transgenic and Knockout Animals in Diagnosis

[0377] This invention also features transgenic and knockout animals that may be used as research tools to determine genetic and physiological features of connective tissue diseases, progeroid disorders, or the cellular damage associated with aging and for identifying therapeutic compounds. Knockout animals also include animals where the endogenous gene has been inactivated or removed and replaced with a known polymorphic or other mutant allele of the gene of interest. These animals can serve as a model system for the risk of acquiring a connective tissue disease or progeroid disorder that is associated with a particular allele.

[0378] In general, the methods of identifying markers associated with a progeroid syndromes, such as Ehlers-Danlos, or connective tissue disease, involves comparing the presence, absence, or level of expression of genes, either at the RNA level or at the protein level, in tissue from an animal and in tissue from a matching unaffected or unaltered animal. Standard techniques for detecting RNA expression, e.g., by Northern blotting, or protein expression, e.g., by Western blotting, are well known in the art. Differences between animals such as the presence, absence, or change in the level of expression of a gene indicate that the expression of the gene is a marker associated with a connective tissue disease or progeroid disorder.

[0379] To assess the effectiveness of a treatment paradigm, a transgene, such as a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene, may be conditionally expressed (e.g., in a tetracycline sensitive manner) and the phenotype assessed. For example, the promoter for the transgene may contain a sequence that is regulated by tetracycline and expression of the sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene product ceases when tetracycline is administered to the mouse. In this example, a tetracycline-binding operator, tetO, is regulated by the addition of tetracycline, or an analog thereof, to the organism's water or diet. The tetO may be operably-linked to a coding region, for example a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene. The system also may include a tetracycline transactivator (tTA), which contains a DNA binding domain that is capable of binding the tetO as well as a polypeptide capable of repressing transcription from the tetO (e.g., the tetracycline repressor (tetR)), and may be further coupled to a transcriptional activation domain (e.g., VP1 6). When the tTA binds to the tetO sequences, in the absence of tetracycline, transcription of the target gene is activated. Binding of tetracycline to the tTA prevents activation. Thus, a gene operably-linked to a tetO is expressed in the absence of tetracycline and is repressed in its presence. Alternatively, this system could be modified such that a gene is expressed in the presence of tetracycline and repressed in its absence. Tetracycline regulatable systems are well known to those skilled in the art and are described in, for example, WO 94/29442, WO 96/40892, WO 96/01313, and Yamamoto et al. (Cell 101:57-66, 2000).

[0380] In another example of conditional expression, FRT sequences may be introduced into the organism so that they flank the gene of interest. Transient or continuous expression of the FLP protein may then be used to induce site-directed recombination, resulting in the excision of the gene of interest. The use of the FLP/FRT system is well established in the art and is described in, for example, U.S. Pat. No. 5,527,695, and in Lyznik et al. (Nucleic Acid Research 24:3784-3789, 1996).

[0381] Conditional, i.e., somatic knockout organisms, may also be produced using the Cre-lox recombination system. Cre is an enzyme that excises DNA between two recognition sites termed loxP. The cre transgene may be under the control of an inducible, developmentally regulated, tissue specific, or cell-type specific promoter. In the presence of Cre, the gene, for example a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene, flanked by loxP sites is excised, generating a knockout. This system is described, for example, in Kilby et al. (Trends in Genetics 9:413-421, 1993).

[0382] Particularly desirable is a rodent model for a progeroid syndrome (e.g., Ehlers-Danlos syndrome) or connective tissue diseases, wherein the nucleic acid having an alteration in a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene, for example, an altered human chondroitin synthase gene, is expressed in the connective tissue cells of the transgenic rodent such that the transgenic rodent develops a progeroid syndrome (e.g., Ehlers-Danlos syndrome) or a connective tissue disorder. The rodents may also contain a sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 transgene, such as one expressing an appropriate (e.g., N-terminally truncated) fragment of sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 under the control of a tissue specific promoter, or have a knockout of the murine sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene. In addition, cell lines from these rodents may be established by methods standard in the art.

[0383] Construction of transgenes can be accomplished using any suitable genetic engineering technique, such as those described in Sambrook et al., (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989). Many techniques of transgene construction and of expression constructs for transfection or transformation in general are known and may be used for the disclosed constructs. Although the use of an altered sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 gene in the transgene constructs is used as an example, wild-type sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 may also be used.

[0384] One skilled in the art will appreciate that a promoter is chosen that directs expression of the chosen gene in the cells which are affected by a progeroid syndrom or a connective tissue disease, for example, connective tissue cells. As noted above, any promoter that promotes expression of sqv-1, sqv-2, sqv-4, sqv-5 or sqv-6 in connective tissue cells can be used in the expression constructs of the present invention. One skilled in the art is aware that the modular nature of transcriptional regulatory elements and the absence of position-dependence of the function of some regulatory elements, such as enhancers, make modifications such as, for example, rearrangements, deletions of some elements or extraneous sequences, and insertion of heterologous elements possible. Numerous techniques are available for dissecting the regulatory elements of genes to determine their location and function. Such information can be used to direct modification of the elements, if desired. It is desirable, however, that an intact region of the transcriptional regulatory elements of a gene is used. Once a suitable transgene construct has been made, any suitable technique for introducing this construct into embryonic cells can be used.

[0385] Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Taconic (Germantown, N.Y.). Many strains are suitable, but Swiss Webster (Taconic) female mice are desirable for embryo retrieval and transfer. B6D2F (Taconic) males can be used for mating and vasectomized Swiss Webster studs can be used to stimulate pseudopregnancy. Vasectomized mice and rats are publicly available from the above-mentioned suppliers. However, one skilled in the art would also know how to make a transgenic mouse or rat. An example of a protocol that can be used to produce a transgenic animal is provided below.

[0386] Production of Transgenic Mice and Rats

[0387] The following is but one desirable means of producing transgenic mice. This general protocol may be modified by those skilled in the art.

[0388] Female mice six weeks of age are induced to superovulate with a 5 IU injection (0.1 cc, IP) of pregnant mare serum gonadotropin (PMSG; Sigma) followed 48 hours later by a 5 IU injection (0.1 cc, IP) of human chorionic gonadotropin (hCG, Sigma). Females are placed together with males immediately after hCG injection. Twenty-one hours after hCG injection, the mated females are sacrificed by CO2 asphyxiation or cervical dislocation and embryos are recovered from excised oviducts and placed in Dulbecco's phosphate buffered saline with 0.5% bovine serum albumin (BSA, Sigma). Surrounding cumulus cells are removed with hyaluronidase (1 mg/ml). Pronuclear embryos are then washed and placed in Earle's balanced salt solution containing 0.5% BSA (EBSS) in a 37.5 C incubator with humidified atmosphere at 5% CO2, 95% air until the time of injection. Embryos can be implanted at the two-cell stage.

[0389] Randomly cycling adult female mice are paired with vasectomized males. Swiss Webster or other comparable strains can be used for this purpose. Recipient females are mated at the same time as donor females. At the time of embryo transfer, the recipient females are anesthetized with an intraperitoneal injection of 0.015 ml of 2.5% avertin per gram of body weight. The oviducts are exposed by a single midline dorsal incision. An incision is then made through the body wall directly over the oviduct. The ovarian bursa is then torn with watchmakers forceps. Embryos to be transferred are placed in DPBS (Dulbecco's phosphate buffered saline) and in the tip of a transfer pipet (about 10 to 12 embryos). The pipet tip is inserted into the infundibulum and the embryos are transferred. After the transferring the embryos, the incision is closed by two sutures.

[0390] A desirable procedure for generating transgenic rats is similar to that described above for mice (Hammer et al., Cell 63:1099-112, 1990). For example, thirty-day old female rats are given a subcutaneous injection of 20 IU of PMSG (0.1 cc) and 48 hours later each female placed with a proven, fertile male. At the same time, 40-80 day old females are placed in cages with vasectomized males. These will provide the foster mothers for embryo transfer. The next morning females are checked for vaginal plugs. Females who have mated with vasectomized males are held aside until the time of transfer. Donor females that have mated are sacrificed (CO2 asphyxiation) and their oviducts removed, placed in DPBA (Dulbecco's phosphate buffered saline) with 0.5% BSA and the embryos collected. Cumulus cells surrounding the embryos are removed with hyaluronidase (1 mg/ml). The embryos are then washed and placed in EBSs (Earle's balanced salt solution) containing 0.5% BSA in a 37.5 C incubator until the time of microinjection.

[0391] Once the embryos are injected, the live embryos are moved to DPBS for transfer into foster mothers. The foster mothers are anesthetized with ketamine (40 mg/kg, IP) and xulazine (5 mg/kg, IP). A dorsal midline incision is made through the skin and the ovary and oviduct are exposed by an incision through the muscle layer directly over the ovary. The ovarian bursa is torn, the embryos are picked up into the transfer pipet, and the tip of the transfer pipet is inserted into the infundibulum. Approximately 10 to 12 embryos are transferred into each rat oviduct through the infundibulum. The incision is then closed with sutures, and the foster mothers are housed singly.

[0392] Generation of Knockout Mice

[0393] The following is but one example for the generation of a knockout mouse and the protocol may be readily adapted or modified by those skilled in the art.

[0394] Embryonic stem cells (ES), for example, 107 AB1 cells, may be electroporated with 25 μg targeting construct in 0.9 ml PBS using a Bio-Rad Gene Pulser (500 μF, 230 V). The cells may then be plated on one or two 10-cm plates containing a monolayer of irradiated STO feeder cells. Twenty-four hours later, they may be subjected to G418 selection (350 μg/ml, Gibco) for 9 days. Resistant clones may then be analyzed by Southern blotting after Hind III digestion, using a probe specific to the targeting construct. Positive clones are expanded and injected into C57BL/6 blastocysts. Male chimeras may be back-crossed to C57BL/6 females. Heterozygotes may be identified by Southern blotting and intercrossed to generate homozygotes.

[0395] The targeting construct may result in the disruption of the gene of interest, e.g., by insertion of a heterologous sequence containing stop codons, or the construct may be used to replace the wild-type gene with a mutant form of the same gene, e.g., a “knock-in.” Furthermore, the targeting construct may contain a sequence that allows for conditional expression of the gene of interest. For example, a sequence may be inserted into the gene of interest that results in the protein not being expressed in the presence of tetracycline. Such conditional expression of a gene is described in, for example, Yamamoto et al. (Cell 101:57-66, 2000).

[0396] These examples are provided for the purpose of illustrating the invention and should not be construed as limiting.

[0397] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

[0398] Other embodiments are within the scope of the claims.

Claims

1. A screening method for identifying a compound that modulates the glycosaminoglycan biosynthetic biological activity of a SQV polypeptide, or fragment thereof, said method comprising the steps of: (a) providing a SQV polypeptide, or fragment thereof, wherein said polypeptide has a glycosaminoglycan biosynthetic biological activity; (b) contacting said polypeptide with a compound; and (c) detecting the level of biological activity of said polypeptide contacted with said compound with the level of biological activity in polypeptide not contacted with said compound; wherein an alteration in said biological activity indicates that said compound modulates the glycosaminoglycan biosynthetic biological activity of a SQV polypeptide.

2. The method of claim 1, wherein said polypeptide is in a mammalian cell.

3. The method of claim 1, wherein said polypeptide is in a nematode cell.

4. The method of claim 1, wherein said nematode cell is in a nematode and said detecting is of a vulval phenotype.

5. The method of claim 1, wherein said detecting is of an enzymatic activity.

6. The method of claim 1, wherein said sqv nucleic acid molecule is selected from the group consisting of a sqv-1, sqv-2, sqv-4, sqv-5, and sqv-6.

7. A method of identifying a compound that modulates a glycosaminoglycan biosynthetic biological activity, said method comprising the steps of: (a) providing a cell comprising a sqv nucleic acid molecule; (b) contacting said cell with a candidate compound; and (c) detecting an alteration in a glycosaminoglycan biosynthetic biological activity of said cell, wherein said alteration identifies said compound as modulating a glycosaminoglycan biosynthetic biological activity.

8. The method of claim 7, wherein said cell is a mammalian cell.

9. The method of claim 7, wherein said cell is a nematode cell.

10. The method of claim 8, wherein said nematode cell is in a nematode and said alteration is of a vulval phenotype.

11. The method of claim 7, wherein said detecting is of an enzymatic activity.

12. The method of claim 7, wherein said detecting is an immunological assay.

13. The method of claim 7, wherein said sqv nucleic acid molecule is selected from the group consisting of a sqv-1, sqv-2, sqv-4, sqv-5, or sqv-6.

14. An isolated sqv-5 nucleic acid molecule, or fragment thereof, that encodes a polypeptide sequence having 35% amino acid sequence identity to SEQ ID NO: 24, wherein said nucleic acid molecule has a glycosaminoglycan biosynthetic biological activity.

15. The isolated nucleic acid molecule of claim 14, wherein said nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 28 or a complement thereof.

16. The isolated nucleic acid molecule of claim 14, wherein said nucleic acid molecule consists essentially of the nucleotide sequence of SEQ ID NO: 28 or a fragment thereof.

17. The isolated nucleic acid molecule of claim 14 further comprising a mutation that corresponds to the mutation identified in sqv-5 (n3039) or n3611.